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Consuming the correct number of calories to maintain a healthy bodyweight is a delicate 
balancing act between intake and energy expenditure, and humans in modern society seem to 
have a keen knack for throwing the balance off-center. In the U.S. alone, more than 1/3 of adults 
are obese based on the body mass index scale, and $147 billion is the estimated annual medical 
cost for obesity in the United States. On the other end of the feeding spectrum, anorexia in the 
U.S. has been steadily rising since the 1960s, and has the highest mortality rate of any mental 
illness. While great strides have been made in understanding the neuronal regulation of energy 
balance, there is a need to more fully understand the homeostatic systems within the 
hypothalamus that are so powerful that they are able to drive individuals to poor health or death, 
often even in the face of consciously fighting their urges. 
Two groups of functionally opposed neurons contained within the arcuate nucleus of the 
hypothalamus, Neuropeptide Y / Agouti-related peptide (NPY/AgRP) and proopiomelanocortin 
(POMC) cells (the so-called first order feeding neurons), have been extensively studied for their 
roles in energy homeostasis—mostly through research into the peptides they are named after. 
There is clear evidence that peptides play an essential role for the function of NPY/AgRP and 
POMC cells, but what about simple amino acid transmitters? While it is known that GABA is 
packaged and released by NPY/AgRP cells and that this release is relevant to feeding behavior, 
iii 
there is still a dearth of information about this aspect of the circuitry, very much an area waiting 
to be mined. 
This study focuses on better understanding the functional release and relevance of amino 
acid transmitters packaged in both NPY/AgRP and POMC cell populations. Evidence is 
presented here for the conclusive release of both GABA and glutamate from POMC cells within 
intact circuitry. For NPY/AgRP neurons, evidence is presented for a shift in functional release of 
GABA from these neurons onto POMC cells depending on feeding state, corroborated by 
concurrent in situ hybridization experiments. Using a combination of electrophysiology and in 
situ hybridization approaches, evidence is also provided that mRNA levels of glutamate 
decarboxylase can act as a general proxy for functional GABA release. 
Altogether, these results indicate that amino acid transmitters play a significant role in 
first order feeding neuron physiology. Not only does this warrant further study on the 
significance of each transmitter alone and their purpose in comparison with the peptides released, 
but also the interplay between POMC cell and NPY/AgRP cell amino acid transmitters and their 
many shared downstream targets. Imbalances in proper glutamatergic and GABAergic signaling 
may significantly contribute to obesity, and advancing this area of study could lead to correcting 
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One of the largest current questions within the science of feeding and energy balance is 
this: with the multitude of targets discovered and much of the neural circuitry known, why hasn’t 
a highly effective drug treatment for obesity been developed? More specifically, it has been 
decades since Jeffrey Friedman’s group discovered the amazing adipogenic satiety peptide 
hormone they named leptin, so why do we currently have a dearth of pharmaceutical treatments 
for obesity, and those that do exist are only marginally better than their side-effects (e.g. 
glucagon-like peptide-1 receptor agonist Saxenda and 5-HT2C receptor agonist Belviq)? The 
simple, as well as lazy, answer is that there is still much unknown in the field, and the search for 
the magic bullet continues. The more descriptive answer is that our current understanding of 
feeding, until recently, was based mostly on a simplistic model of yin and yang (signals of 
hunger and satiety), which lacked the depth of receptor complexity, asymmetric circuitry, 
pathway redundancy, and neurotransmitter variety present in a complete model. The field has not 
yet reached full maturity, but recent advances in technology, especially genetic and imaging 
tools, have allowed for great strides to be made in the past few years. Pertinent to the primary 
research in this study, one area largely ignored but now starting to become a topic of interest is 
amino acid transmitter release from first order feeding neurons. To understand the complex 
picture of where the knowledge gaps currently lie, where the primary research in this study fits, 
and where the field should be going next requires background detailing obesity and 
hypothalamic control of energy homeostasis, including the current prevailing paradigms and the 
biological players within them. The purpose of this introductory chapter is to provide this 
information, as well as to provide context for the primary research contained in chapters 2 and 3. 
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1.1 Obesity 
  Weighing too much is a problem individuals are battling worldwide. Obesity is now 
considered a chronic disease or metabolic syndrome and is defined by excess body fat and is 
accompanied by various comorbidities. The quantifiable measure for estimating the weight 
health of a person is by utilizing the body mass index (BMI = weight in kilograms divided by the 
square of height in meters [kg/m2]). For adults a BMI of 18.5 to 24.9 is considered normal. BMI 
greater than 25 is considered as overweight, and a BMI larger than 30 and 40 indicate obesity 
and morbid obesity respectively (WHO, 2000). While BMI may occasionally be a poor measure 
of individual health (e.g. body builders or professional athletes), it is a good indicator of 
overweight on a population level. Although obesity may be plateauing in the United States, the 
obesity epidemic remains a public health crisis, with over 1/3 of adults and 16.9% of children 
being classified as obese in a 2011-2012 survey (Ogden et al., 2014). Worldwide, studies find 
that the prevalence and severity of obesity is increasing rapidly in children, adolescents, and 
adults (Wang and Lobstein, 2006; Chan and Woo, 2010). 
 It is known that obesity is associated with a number of chronic diseases spread across 
both adults and children including type 2 diabetes, hypertension, dyslipidemia, disturbed glucose 
tolerance, and some forms of cancer (Kelly et al., 2008; I'Allemand et al., 2008; Mauras et al., 
2010). Perhaps unsurprisingly, this leads to a connection between obesity and a shortened 
lifespan (Biro and Wien, 2010). While inexpensive and seemingly simple life changes early on 
could prevent negative health outcomes, living with chronic obesity drives significant health care 
costs in order to treat the disease, its comorbidities, and prevent mortality (Ebbeling et al., 2002; 
Yach et al., 2006; John, 2010; Muller-Riemenschneider et al., 2008; Finkelstein et al., 2009). 
Knowing exactly what causes obesity and finding as many appropriate treatments as possible 
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would obviously be a boon to humanity worldwide, reducing suffering and excess spending. A 
frantic race in the scientific community is now underway to unravel the mechanisms involved 
and build potential therapeutic strategies, spurred on by the urge to understand the fundamental 
determinants of obesity and obesity-related disease. 
So what is known about feeding circuitry, the disruption thereof, and how the body 
controls the homeostatic set point? Whereas some genetic loci have been clearly identified, and 
extensively studied as monogenic causes for obesity, it is widely accepted that the metabolic 
syndrome is in essence a multifaceted disease that encircles a complex network of molecular, 
cellular and physiologic alterations (Kopelman and Hitman, 1998; Kahn and Flier, 2000). 
Ultimately, the brain must coordinate the activity of peripheral tissue to insure the fate of some 
nutrients once ingested. The brainstem works at a basic and essential level to provide satiety 
behaviors (Grill and Norgren, 1978; DiRocco and Grill, 1979), but without a complete neural 
network, challenges to homeostasis cannot be countered by adjustments in physiology (Seeley et 
al., 1994; see Grill and Kaplan, 2001 for review). It is understood that the hypothalamus is where 
the core of much of this complex modulatory activity occurs, but it is conceptually easier to start 
with food actually entering the body and taking it from there. The following sections will start at 
the periphery and head into the central nervous system. 
  
1.2 Endocrine and peripheral input into the central nervous system 
 Much of the regulation of food consumption in the short term is driven by gastrointestinal 
peptides that are released directly after food is consumed (see Havel, 2001). These hormones will 
travel through the blood and directly or indirectly (through the vagus nerve up the general 
visceral afferent pathway) interact with the nucleus tractus solitarius (NTS), an area at the base 
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of the brainstem known for forming circuits that contribute to autonomic regulation (see Holzer 
and Farzi, 2014; Svendsen and Holst, 2015). The NTS can be considered one of the major satiety 
centers in the CNS, collating and making sense of the peripheral signals coming from the 
stomach, liver, and both small and large intestines to regulate satiety. Through the interaction 
with the NTS, as well as direct interaction with neurons in the arcuate nucleus of the 
hypothalamus (ARC), these hormones, with the exception of ghrelin, induce satiety and 
cessation of food intake. Examples include cholecystokinin (CCK) from the duodenum and 
jejunum, glucagon-like peptide-1 (GLP-1) from the ileum and colon, gastrin-releasing peptide 
(GRP) from the stomach, and peptide YY (PYY) from the ileum and colon. The mechanisms by 
which CCK promotes satiety are through delaying gastric emptying and activating the vagal 
afferent nerves that innervate the NTS (Schwartz et al., 1999). GLP-1 functions in many ways, 
including acting as an insulin secretagogue, slowing gastric emptying and forcing food to stay in 
the stomach for longer periods of time, and binding to receptors on afferent nerves in the liver 
and GI tract, thereby relaying satiety signals to the NTS (Moran, 2009). GRP promotes satiety 
mostly through delaying gastric emptying (Merali ey al., 1999). PYY is released in response to a 
meal and reduces appetite by slowing gastric emptying (Moran, 2009). In contrast to the satiety-
inducing (anorexigenic) actions of many gut hormones associated with the regulation of food 
intake, ghrelin is an octanoylated orexigenic peptide that is produced by the stomach, and to a 
lesser extent, the intestine and arguably the hypothalamus (Kojima et al., 1999; Havel, 2001). 
Plasma concentrations of ghrelin peak immediately before a meal and drop off quickly after a 
meal has been consumed (Cummings et al., 2001), acting on the G-protein coupled ghrelin 
receptors within the CNS to exert its metabolic effects (Guan et al., 1997; Mitchell et al., 2001; 
Zigman et al., 2006). In addition to the gastrointestinal peptides, mechanoreceptors in the 
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stomach and small intestines play a role in the short-term regulation of food intake. These 
receptors respond to the presence of food in the stomach and small intestines by transmitting 
signals via the vagal afferents to the hindbrain to initiate meal termination (Page et al., 2002; 
Carmagnola et al., 2005). Most of these gut signals are thought to act in the short term, while two 
other feeding-related hormones, insulin and leptin, are seen as longer-term players. 
 Whereas the short-term satiety signals often act upon the NTS in the brainstem, other 
circulating factors primarily interact with the various nuclei of the hypothalamus, including the 
ARC, paraventricular (PVN), ventromedial (VMH), and lateral (LH) nuclei (see Myers et al., 
2008). One such factor is the adipogenic hormone, leptin. The idea of a signal from fat 
interacting with feeding centers in the hypothalamus goes back over half a century with Kennedy 
and what became to be known as the lipostatic hypothesis (Kennedy, 1953). It took until 1994, 
when the leptin gene was first cloned, to find Kennedy’s adipogenic signal (Zhang et al., 1994). 
Leptin is produced by white adipose tissue, and plasma levels of leptin increase when the body 
has a surplus of energy available, especially when adipose tissue increases (Halaas et al., 1995; 
Friedman, 2009). One of the key signaling mechanisms driving the neuroendocrine, metabolic, 
and behavioral adaptations that promote a decrease in energy expenditure and increase food 
intake is a fasting-induced decrease in leptin (Ahima et al., 1996; see Myers et al., 2008). The 
importance of leptin in maintaining energy balance over the long term is highlighted by studies 
showing that leptin deficiencies or defects in the leptin receptors in the brain can cause 
hyperphagia and severe obesity (Montague et al., 1997; Clement et al., 1998; Strobel et al., 
1998). Leptin-responsive neurons express the long-form of leptin receptor (LepRb), which is a 
single-trans-membrane-domain protein of the cytokine receptor family that operates through the 
JAK-STAT signaling cascade. This specific receptor variant is required for leptin's central 
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effects and is highly expressed within several CNS sites, including hypothalamic nuclei 
(Elmquist et al., 1998, 2005; Scott et al., 2009). One interesting aspect of leptin is its opposing 
role to ghrelin. Many of the same areas of the brain contain receptors for both hormones, leading 
naturally to a push/pull hypothesis because of the overlap (see Nogueiras et al., 2008). However, 
both receptors have quite distinct profiles within the CNS, and deletion of the ghrelin receptor 
does not affect leptin sensitivity, casting doubt on a simple relationship (Perello et al., 2012). 
Insulin is another major player in energy homeostasis, but its role in the CNS is not as 
understood as in the periphery. Insulin is secreted from the beta cells of the pancreas in response 
to the ingestion of food, which promotes the absorption of glucose from blood to skeletal 
muscles and adipose tissue, causes fat to be stored rather than used for energy, and inhibits 
gluconeogenesis (Sonksen and Sonksen, 2000). Although insulin clearly has satiating effects in 
the CNS (Woods et al., 1979; Hallschmid et al., 2004; Brown et al., 2006), the physiological 
significance of these actions remains uncertain. For example, injecting an antisense 
oligonucleotide into the third ventricle in order to curtail insulin receptor expression in 
hypothalamic nuclei caused immediate and significant hyperphagia (Obici et al., 2002), but 
neural insulin receptor knockout strategies have found little to no phenotype in mice (Brüning et 
al., 2000; Choudhury et al., 2005). With a base of information on the link between peripheral 
signals and the CNS covered, this is an appropriate place to transition completely into the CNS, 
specifically regarding the hypothalamus and surrounding feeding circuitry.   
 
1.3 Hypothalamic regulation of energy balance 
Implication of the hypothalamus in feeding and energy balance goes as far back as 1840, 
when hypothalamic obesity was described by Mohr (1840). He noticed that a woman had 
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become obese within a year before her death, and upon autopsy of this woman, Mohr found a 
hypophysial tumor compressing and distorting the base of the brain. There was no attempt to 
connect the increase in adiposity to a hypophysial or hypothalamic injury, but this report and 
clinicians making other reports like it set the stage for new understanding of this brain region. 
Over decades, a controversy developed between those that thought pituitary dysfunction 
(Fröhlich, 1901) and those that thought purely neural dysfunction (Erdheim, 1904) was to blame 
for hyperphagia and increased adiposity in these case studies, and it was not until 1930 that 
enough empirical evidence was amassed to end the controversy for good (see Aschner, 1912; 
Smith, 1930 for best examples). Soon after the Horsley-Clarke stereotaxic instrument was 
adapted for rats in 1939, relatively more refined electrolytic lesion studies were performed to 
provide the first undeniable evidence that the hypothalamus is the central hub for feeding 
(Hetherington and Ranson, 1940, 1942). Lesions to the base of the hypothalamus produced such 
hyperphagia that rats recovering from the surgery were observed to begin eating voraciously 
even before the anesthesia had worn off, to the extent of dying from asphyxiation because their 
swallowing reflex had not yet returned (Brobeck et al., 1943). Later, somewhat more 
sophisticated, lesion studies would define specific areas of the hypothalamus, especially the 
ARC, as being responsible for feeding and energy balance (Nemeroff et al., 1978; Penicaud et 
al., 1983; Sims and Lorden, 1986). 
Referring to the peptide hormones discussed in the latter portion of 1.2, ghrelin, leptin, 
and insulin, what makes the hypothalamus, and specifically the ARC, such an exquisite target for 
their actions? What makes this area specialized to its job is suggested by the unique anatomy 
within the region. The ARC is located in the ventral portion of the brain, at the bottom of the 
third ventricle, directly next to the median eminence (ME), which is one of the circumventricular 
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organs (CVO). The “leaky” blood-brain barrier at CVOs allows for selective exchange of 
substrates between in the blood and cerebrospinal fluid, eventually allowing contact to the neural 
tissue in the ARC. Regulation of food intake and energy homeostasis depends on the ability for 
hormones from the periphery to effect change directly at neurons charged with that task. These 
neurons, termed “first order” feeding neurons integrate signals circulating through the blood and 
encode energy signals into synaptic transmission that will affect downstream secondary neurons. 
Unsurprisingly, these downstream neurons have earned the moniker of “second-order” feeding 
neurons. Tanycytes, from the Greek word tanus, which means elongated, are the specialized 
hypothalamic glial cells that act as gatekeepers of the blood-brain barrier and allow for exchange 
across it (Gao et al., 2014). Tanycytes extend from the ependymal surface (thus making them a 
specialized type of ependymal cell) of the third ventricle to a bed of permeable fenestrated 
capillaries (Langlet et al., 2013). Energy state-signaling hormones, such as ghrelin and leptin, are 
able to quickly pass through and relay their relevant actions (Schaeffer et al., 2013; Balland et 
al., 2014). These features ultimately define why first order feeding neurons are so poised to 
rapidly adapt, making electrophysiological changes is response to hunger or satiety signals, and 
continue carrying out their functions. 
 
First order feeding neurons: POMC cells and NPY/AgRP cells 
The ARC contains (at least) two major populations of neurons that are crucial for 
monitoring energy signals and subsequently pushing for the suitable behavioral and metabolic 
responses to alterations of energy state (see Figure 1.1 for relative location in the brain). The first 
group of neurons is proopiomelanocortin (POMC) neurons, understood to promote satiety and 
named after the propeptide these cells produce and utilize (Xu et al., 2011; Myers and Olson, 
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2012). POMC is cleaved by processing enzymes in a tissue-specific manner, resulting in a 
handful of bioactive peptides. Outside of the ARC, in the corticotrophs located in the anterior 
pituitary, POMC is translated and cleaved to make adrenocorticotropic hormone (ACTH), which 
is released into the blood where it regulates stress hormone production and release from adrenal 
glands (Wardlaw, 2011). Relevant to feeding, in the mouse ARC, POMC is expressed in a fairly 
evenly spread group of a few thousand neurons (Cowley, 2001; Jarvie, 2012), where it is 
processed into α- and γ-melanocyte stimulating hormone (α-MSH and γ-MSH) and the opioid β-
endorphin (Wardlaw, 2011). α-MSH, γ-MSH, and ACTH are all referred to as melanocortins 
because they agonize melanocortin receptors. All five melanocortin receptors are G-protein 
coupled receptors (GPCRs). The MC3R and MC4R are the receptors located in the CNS (Cone, 
2005; Kim et al., 2014), while the other three carry out quite unrelated activities, such as skin 
pigmentation and exocrine gland function. The discovery that injection of melanocortins into the 
CNS inhibited both spontaneous and drug-induced feeding in rats suggested that POMC neurons 
might be able to sense and respond to indicators of feeding state (Poggioli et al., 1986). Although 
most of the peptides POMC cells release have an impact on feeding, effects on the suppression 
of food intake have been primarily attributed to α-MSH signaling (Brown et al., 1998; Thiele et 
al., 1998). Injections of α-MSH, as well as the α-MSH synthetic analogue melanotan-II (MTII), 
into the ventricles caused a highly significant decrease in food consumption (Thiele et al., 1998). 
MTII injection into the PVN also produces reduction in eating, which is prevented by 
coadministering an AgRP analogue (Fan et al., 1997). 
The second ARC population of first order neurons which are essential for regulation of 
feeding are the neurons that make neuropeptide Y (NPY) and Agouti-related protein (AgRP) 



















(Tatemoto et al., 1982), but it wasn’t until a couple years later that one of its functions was 
characterized as an orexigenic peptide (Clark et al., 1984). NPY agonizes a set of G-protein 
coupled NPY receptors (Linder et al., 2008). Infusion of NPY into the cerebral ventricles also 
causes an increase in eating (Clark et al., 1984; Levine and Morley, 1984; Stanley et al., 1985). 
Targeted infusion of NPY into subregions of the hypothalamus revealed the PVN, VMH, and LH 
as key areas involved in NPY-regulated eating (Stanley et al., 1985). AgRP was discovered as an 
Figure 1.1. Opposing first order feeding neuron populations are located in the arcuate 
nucleus of the hypothalamus. (A) Coronal section of an adult mouse brain containing the ARC. 
White triangle encompasses arcuate nuclei and ME. NPY/AgRP cells are densely packed near the 
ME, visualized using an NPY-hrGFP animal and presented as a confocal Z-stack (B). POMC cells 
are relatively more spread through the ARC and slightly larger than NPY/AgRP cells, visualized 
using a POMC-DsRed animal (C). 3v, third ventricle. Scale bar for (A) is 500 µm, while scale bar 
for (B) is 100 µm. 
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inverse agonist for the melanocortin receptors (Ollmann et al., 1997; Shutter et al., 1997), which 
led to the colocalization of the two peptides (Hahn et al., 1998). 
Previous work with the agouti gene (different than the AgRP gene) actually led to the 
hypothesis of opposing feeding neuron populations harnessing the melanocortin system. The 
agouti gene was cloned in 1992 (Bultman et al., 1992) and was the first obesity gene to be 
characterized at the molecular level. Hair follicles express agouti, where it leads to the 
production of yellow and red pigments and inhibits the production of black pigments in 
melanocytes. The mechanism through which agouti acts on melanocytes is by antagonizing 
MC1Rs. The lethal yellow (Ay) mutation is one of five known agouti mutations that leads to 
ectopic agouti expression (Michaud et al., 1994). Heterozygotes (homozygous expression of this 
spontaneous mutation is lethal), in addition to their yellow hair color, develop obesity within the 
first few months of life. This is because ectopic expression of agouti in the hypothalamus 
functionally outcompetes α-MSH at MC3 and MC4Rs. 
Like the effect of constitutively expressed agouti, infusion of AgRP into ventricles causes 
increases in food intake, which is prevented with simultaneous injection of melanocortin agonists 
(Hagan et al., 2000). NPY/AgRP cells not only release peptide neurotransmitters, they also 
release the amino acid transmitter γ-aminobutyric acid (GABA), providing NPY/AgRP neurons 
with another inhibitory mode of action (Horvath et al., 1997). Recent counts put the number of 
these neurons at about 10,000 in the mouse brain (Betley et al., 2013). 
 
Satiety and POMC vs. hunger and NPY/AgRP: paradigm of opposition 
 The classical paradigm for opposing first order feeding neurons continues as the standard 
model with the decades’ worth of literature behind it. Collectively, POMC and NPY/AgRP 
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neurons, their projecting fibers, target neurons expressing MC3R or MC4R, and a second small 
group of POMC-expressing neurons in the brain stem, define the neural melanocortin system 
(Mountjoy et al., 1994; Zhan et al., 2013). Through a combination of pharmacology experiments, 
electrophysiology, and knockout mouse models, a model of energy homeostasis was formed 
(Figure 1.2). Early hypotheses stated that two battling peptides, α-MSH and AgRP, act on the 
MC3 and MC4 melanocortin receptors throughout the brain to directly regulate food intake and 
energy balance. α-MSH-induced activation of melanocortin receptors decreases food intake and 
increases energy expenditure, and AgRP antagonizes these effects (Fan et al., 1997; Hagan et al., 
2000). This idea is consistent with the finding that POMC and NPY/AgRP cells share common 
second order targets in the CNS that are located in the PVN, LH, VMH, and dorsomedial (DMH) 
nuclei of the hypothalamus, as well as extrahypothalamic regions like the NTS and parabrachial 
nucleus (PBN) (Bagnol et al., 1999; Wang et al., 2015). POMC-KO and MC4R-KO mice are 
hyperphagic and obese, and MC3R-KO mice have increased fat mass (Huszar et al., 1997; 
Yaswen et al., 1999; Butler et al., 2000). AgRP-KO mice have no metabolic phenotype (Qian et 
al., 2002), however, acute ablation of NPY/AgRP neurons in adulthood using targeted diphtheria 
toxin receptor causes starvation (Wu et al., 2008). This evidence of the importance of peptide 
transmitters was used to build and sustain the basic opposing force model. 
 Circulating hormones directly and indirectly modulate the two pools of first order feeding 
neurons. A lot of study has been devoted to leptin, which activates POMC neurons and increases 
transcription of POMC mRNA levels, at the same time inhibiting NPY/AgRP neurons and 
decreasing AgRP mRNA levels through direct activation of LepRb, which is expressed on both 
cell types (Schwartz et al., 1997; Mizuno and Mobbs, 1999; Elias et al., 1999; Lam et al., 2015). 
Electrophysiologically, there is some evidence, although not yet completely convincing, that 
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Figure 1.2. Classical paradigm of opposing first order feeding neurons. Circulating energy signals reach the 
median eminence where they are able to cross the weak blood-brain barrier (BBB). POMC and NPY/AgRP cells 
are excited or inhibited by these signals, which alters the balance between the populations of neurons and allows 
for appropriate autonomic and behavioral food intake and energy expenditure actions to occur. POMC neurons 
activate downstream 2nd order feeding neurons by releasing α-MSH onto melanocortin 4 receptors (MC4Rs). 
NPY/AgRP neurons fight this activation by releasing the MC4R antagonist AgRP, in addition to releasing NPY 
onto the inhibitory NPY type 1 receptors (Y1Rs). NPY/AgRP cells directly inhibit POMC cells through 
activation of Y1Rs and putative GABA release onto GABAA receptors, while POMC cells directly inhibit 
NPY/AgRP cells through putative activation of melanocortin 3 receptors (MC3Rs). 
 
 14
leptin signaling depolarizes POMC neurons via activation of TRPC channels (Qiu et al., 2010), 
whereas NPY/AgRP neurons are hyperpolarized by activation of the Kv2.1 potassium channel 
(Baver et al., 2014). Because POMC cells are innervated by NPY/AgRP neurons (Atasoy et al., 
2012), leptin is also able to depolarize POMC neurons through reduction of inhibitory tone from 
AgRP NPY, as well as GABA, release (Cowley et al., 2001). Even though leptin inhibits 
NPY/AgRP neuron activity, it is actually required during early life development in order to 
properly wire. Mice genetically deficient of leptin (ob/ob) or its receptor (db/db) display 
abnormal projections to the PVN (Bouret et al., 2004; 2012) from ARC feeding neurons, 
pointing to a role as a trophic factor in neonates. Ghrelin also acts directly on first order neurons. 
It was shown to directly increase the firing rate of NPY/AgRP neurons, as well as indirectly 
inhibit POMC neurons by increasing inhibitory tone from NPY/AgRP cells onto POMC cells 
(Cowley et al., 2003). The ghrelin receptor is a Gα11/Gq11-coupled GPCR that activates 
phospholipase C (PLC). PLC increases the intracellular Ca2+ levels through inositol-3-phosphate 
(IP3) and protein kinase C pathways (van der Lely et al., 2004; Ferrini et al., 2009). In addition to 
these peptides, POMC and AgRP neurons are now known to also respond to estrogen, glucose 
and fatty acids in an opposing manner (Ibrahim et al., 2003; Chang et al., 2005; Titolo et al., 
2006; Jo et al., 2009; de Souza et al., 2011; Koch and Horvath, 2014). 
Using the Cre-lox system with POMC- and NPY/AgRP-Cre animals continues to be a 
popular method to find out how these two populations of neurons function and interact. 
However, careful attention must be paid not to overstate results when using these strategies, 
especially in light of recent findings that POMC is transiently expressed during development in 
cells fated to become NPY/AgRP or Kisspeptin neurons (Padilla et al., 2010; Sanz et al., 2015). 
Any meaningful amount of Cre being expressed in unintended neurons will cause permanent 
 15
recombination of floxed sites. For examples of work that may warrant alternative interpretation, 
see Balthasar et al., 2004 and Xu et al., 2008. Some of the most convincing evidence for the 
basic idea of first order feeding neuron opposition comes from the development of optogenetic 
tools. Through expression of the light-gated nonselective cation channel, channelrhodopsin-2 
(ChR2), it is possible to selectively activate molecularly marked neurons using a specific 
wavelength of light (Boyden et al., 2005; Arenkiel et al., 2007). Optogenetic stimulation of even 
a minority of NPY/AgRP cell bodies in vivo rapidly elicits an insatiable appetite and food 
consumption in mice, even if they have recently eaten a meal (Aponte et al., 2011). This effect 
scales with frequency of light stimulation. Conversely, light stimulation of POMC neurons 
decreases food intake and body weight, although a longer period of stimulation is needed to 
observe significant effects (Aponte et al., 2011). This difference between neuron types might be 
attributable to the timescales in which different neurotransmitters act. Interestingly, when Ay 
mice that are constitutively producing agouti protein, which binds melanocortin receptors and 
prevents changes in the natural melanocortin system to have any effect, are used, NPY/AgRP 
stimulation still causes feeding behavior and weight gain, while POMC cell stimulation has no 
effect on feeding (Aponte et al., 2011). This implies that, at least in that paradigm, melanocortin 
signaling is much more important for POMC cells than for NPY/AgRP cells, which could be 
relying on the fast actions of their amino acid transmitter, GABA. This is just one caveat to the 
simple idea of opposing actions of first order feeding neurons specifically at melanocortin 





Wrinkles in the classical paradigm 
While the dueling melanocortin idea of feeding is still established and accepted, the field 
is rapidly growing beyond a simple model (for excellent contemporary reviews, see Mountjoy, 
2015; Sternson and Atasoy, 2014). Advances in imaging and recording approaches have allowed 
for the development of in vivo calcium imaging. In line with ex vivo brain slice recordings, 
NPY/AgRP neurons are active during the fasted state and also respond with elevated calcium 
events to injections of ghrelin. The surprising and more novel finding, however, is that POMC 
and AgRP neurons respond rapidly to sensory food cues even before ingestion, and the response 
varies with nutritional state and depends on the palatability of the food presented (Betley et al., 
2015; Chen et al., 2015); the fast response is caused by detection, not consumption. Thus, in 
addition to long-term integration of nutritional signals and maintenance of energy balance, the 
melanocortin system is poised to be dynamically regulated by sensory stimuli and may be 
directly involved in food-seeking behavior. 
One conceptually simple finding to keep in mind is that POMC and AgRP neurons often, 
but not always, project to the same nuclei. This suggests that some areas of the brain utilize 
independent branches of the first order feeding neuron populations, implicating a possible role 
for each peptide independent of the other (Wang et al., 2015). It could be possible that there is 
constitutive activity of the melanocortin receptors in some brain regions, and there is some 
evidence to suggest that AgRP could act alone on a receptor as an inverse agonist rather than just 
a competitively binding antagonist (Tao, 2014). One hint at an alternate hypothesis lies with 
recent investigation into the signaling cascade downstream from the MC4R. Although α-MSH 
and opposing AgRP action on MC4Rs is transduced though a Gs-coupled pathway (Nickolls et 
al., 2005; Buch et al., 2009), recent findings are suggesting the somewhat controversial idea that 
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AgRP acts in a second, Gs-independent manner on the MC4R. Specifically, that there is  
coupling of the MC4R to the inward-rectifying potassium channel Kir 7.1 (Ghamari-Langroudi 
et al., 2015). 
As previously discussed, AgRP-KO mice have no metabolic phenotype, while ablation of 
NPY/AgRP neurons in an adult results in starvation (Wu et al., 2008). This suggests 
developmental compensation, but in what manner? Further study revealed that the starvation was 
melanocortin-independent, and that proper hunger signaling and was mediated at least in part by 
the amino acid transmitter GABA (Wu et al., 2008; 2009; 2012). In addition, two methods of 
targeted neural activation (cell-type-specific light- or chemical-mediated activation) show that 
excitation of AGRP neurons leads to immediate and voracious feeding, also independent of 
melanocortin signaling (Krashes et al., 2011; 2013). Through additional experiments, it was 
determined that NPY and GABA released by NPY/AgRP neurons both play a significant role in 
the short-term feeding behavior, whereas AgRP might be more responsible for feeding on a 
longer time scale (Krashes et al., 2013). 
POMC neurotransmitter release is not restricted to peptides; before beginning the primary 
research in this study, our lab had previously discovered that POMC cells release both GABA 
and glutamate in autaptic cultures (Hentges et al., 2009), although it was unknown if that 
phenotype held in intact circuitry or what physiological relevance amino acid transmitter release 
might hold. Further discussion will be found in later chapters, but to summarize, very little is 
known about the relevance of POMC amino acid transmitters. There is a small amount of 
evidence that there are two classes of POMC cell neurotransmitter release sites—one that 
releases a combination of neurotransmitters and peptides at conventional synapses, and the other 
being extrasynaptic sites that only release peptides (Atasoy et al., 2014). Clearly, the recent 
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findings described point toward a more complex feeding and energy homeostasis model that 
must account for separate mechanisms on separate timescales, redundancy, developmental 
adaptation, and importance of amino acid transmitters. 
 
Beyond first order neurons 
 Where do POMC and NPY/AgRP neurons exert their largest effects? One way to answer 
this is to know in what brain regions melanocortin receptors are most necessary for proper 
feeding and energy balance. A group using the Mc4rloxTB/loxTB mouse line, a global MC4R 
knockout that will re-express MC4R if Cre is introduced, along with a Sim1-Cre line, MC4Rs 
were only expressed in the amygdala, nucleus of the lateral olfactory tract, DMH, and LH 
(Balthasar et al., 2005). This selective expression drastically diminished the increased body 
weight phenotype observed in the Mc4rloxTB/loxTB mouse model, but it was not a complete rescue, 
suggesting at least some relevant melanocortin activity outside of these brain regions. Further 
targeting of the PVN with a selective knockout Mc4rlox/lox mouse line, in conjunction with the use 
of the previous selective rescue line and some elegant use of Cre-expressing viral injections, 
showed that melanocortin activity specifically in the PVN is both necessary and sufficient for the 
majority of a proper weight phenotype (Shah et al., 2014). This study did a great job in 
essentially using a brute-force strategy to determine the relevance of other types of neurons to 
the melanocortin system. Loss or rescue of MC4Rs in glutamatergic neurons using the vGLUT2 
glutamate transporter accounted for a complete loss or rescue of a weight phenotype, whereas re-
expression in oxytocin, corticotropin-releasing hormone, arginine vasopressin, or prodynorphin 
neurons (all expressed within the PVN) had no measured effect. Interestingly, although the PBN 
is part of a known feeding pathway (Carter et al., 2013), regaining any expression of MC4Rs in 
 19
the PBN results in no change in phenotype, suggesting that a melanocortin-dependent role of 
function is lacking in the region, that GABA release is the relevant first order transmitter 
released in the pathway, and/or that the pathway is not relevant to feeding outside extreme 
physiological states e.g. being poisoned or very sick. 
The PBN is actually a heavily researched area at this time, as a second group of neurons 
more lateral to those studied in Carter et al., 2013 is generating interest for being a major efferent 
target for the effects of MC4R-expressing PVN neurons. ChR2-mediated stimulation of 
terminals of MC4R-expressing PVN neurons located in the lateral PBN caused the same 
reduction in feeding behavior as activation at the soma level (Garfield et al., 2015). Although the 
pathway flowing through the glutamatergic PVN neurons is currently being heavily mined for 
information, there are other groups of relevant second order neurons that are innervated by both 
POMC and NPY/AgRP cells. However, results between groups have been mixed. Terminal field 
photostimulation of ChR2-expressing NPY-AgRP neurons in the anterior bed nucleus of the stria 
terminalis (aBNST) and LH promotes acute food consumption to comparable levels as that 
observed following NPY/AgRP soma activation (Atasoy et al., 2012; Betley et al., 2013; 
Sternson lab), but patch clamp recordings of MC4R-expressing cells in those regions while doing 
the same photostimulation of NPY/AgRP cells found no evidence for monosynaptic inhibitory 
connections (Garfield et al., 2015; Lowell lab). These pathways need further clarification. It may 
be that there is a complex system of interneurons between NPY/AgRP cells and their LH targets, 
or that the orexigenic nucleus in the LH is mostly under the control of POMC cells, but further 




1.4 General hypotheses and aims of the study 
 With obesity being such a significant problem in Western society, there is an obvious 
need to more fully understand the homeostatic systems within the hypothalamus that drive 
feeding and energy balance. In reviewing some of the most important feeding literature currently 
published, context has been given for the primary research in this study. To summarize the ideas 
and concepts most relevant to the following chapters, NPY/AgRP and POMC neurons located in 
the ARC have been studied extensively for their opposing regulation of energy homeostasis. 
NPY/AgRP neurons express increased markers of activation, such as FOS during a fasted or 
hungry state (Wu et al., 2014). Conversely, POMC neurons show greater markers of FOS during 
a sated rather than a fasted state (Wu et al., 2014). The responsiveness of these cell types to 
changes in feeding state clearly points to their role as important players in feeding and energy 
balance circuits. Because of their exquisite placement next to a CVO and their ability to detect 
energy state signals in the bloodstream, it is no surprise that these two groups of cells are thought 
to represent the primary initial node in the feeding model of the mammalian brain. 
So far, the majority of study has examined the peptide transmitters that these first order 
feeding neurons release and are named for, which are clearly important for normal control of 
feeding and weight. However, only a small portion of obesity can be explained by perturbations 
or mutations in the first order feeding neuron peptide systems (van Vliet-Ostaptchouk et al., 
2009). While these peptides are clearly important for proper maintenance of body weight, 
classical amino acid transmitters may also play a significant role in POMC cell physiology (van 
den Pol, 2003; Meister, 2007), and definitely play an important role in NPY/AgRP cells’ ability 
to modulate feeding behavior (Aponte et al., 2011; Wu et al., 2012; Krashes et al., 2013; Carter 
et al., 2013). GABA has been long known to affect feeding (Kelly et al., 1977; Tsujii and Bray, 
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1991), and the GABA receptor continues to be a potential target for eating disorder and obesity 
treatment (Guardia et al., 2011). 
 The first aim of this study is to test the hypothesis that both glutamate and GABA are 
released from POMC cell terminals, and that this release is relevant to the feeding circuit. 
Chapter 2 addresses release, and while there is still little evidence for relevance, new findings 
from our lab are discussed in Chapter 4. 
 The experiments in Chapter 3 test the hypothesis that GABA release from NPY/AgRP 
cells is regulated based on feeding state, focusing specifically on the non-reciprocated direct 
synaptic connection of NPY/AgRP cells to POMC cells. Additionally, through in situ 
hybridization experiments, glutamate decarboxylase mRNA (Gad) level as a proxy for functional 
GABA release is discussed as a broadly applicable tool. The importance of inhibitory tone from 
NPY/AgRP neurons onto POMC neurons is discussed in Chapter 4. Both aims rely heavily on a 
combination of electrophysiology and optogenetic techniques to obtain pseudo-paired 
recordings.    
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2. REGULATION OF GABA AND GLUTAMATE RELEASE FROM 





Hypothalamic proopiomelanocortin (POMC) neurons and their peptide products mediate 
important aspects of energy balance, analgesia, and reward. In addition to peptide products, there 
is evidence that POMC neurons can also express the amino acid transmitters GABA and 
glutamate, suggesting these neurons may acutely inhibit or activate downstream neurons. 
However, the release of amino acid transmitters from POMC neurons has not been thoroughly 
investigated in an intact system. In the present study, the light-activated cation channel 
channelrhodopsin-2 (ChR2) was used to selectively evoke transmitter release from POMC 
neurons. Whole-cell electrophysiologic recordings were made in brain slices taken from POMC-
Cre transgenic mice that had been injected with a viral vector containing a floxed ChR2 
sequence. Brief pulses of blue light depolarized POMC-ChR2 neurons and induced the release of 
GABA and glutamate onto unidentified neurons within the arcuate nucleus, as well as onto other 
POMC neurons. To determine if the release of GABA and glutamate from POMC terminals can 
be readily modulated, opioid and GABAB receptor agonists were applied. Agonists for mu and 
kappa, but not delta, opioid receptors inhibited transmitter release from POMC neurons, as did 
the GABAB receptor agonist baclofen. This regulation indicates that opioids and GABA released 
from POMC neurons may act at presynaptic receptors on POMC terminals in an autoregulatory 
                                                 
1 Full article from Dicken MS, Tooker RE, and Hentges ST. (2012) The Journal of Neuroscience, 32:4042-4048. 
Shane Hentges contributed to experimental design and writing of the manuscript. Ryan Tooker performed initial 
ChR2 experiments and edited the manuscript. Matthew Dicken performed the majority of the experiments, analyzed 
collected data, assisted in experimental design, and contributed in writing the manuscript. 
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manner to limit continued transmission. The results show that in addition to the relatively slow 
and long-lasting actions of peptides, POMC neurons can rapidly affect the activity of 
downstream neurons via GABA and glutamate release. 
 
2.2 Introduction 
Hypothalamic proopiomelanocortin (POMC) neurons are thought to exert their effects on 
energy balance, motivation, pain and reward mainly through release of the mature POMC 
cleavage products α-melanocyte-stimulating hormone (α-MSH) and β-endorphin (Coll, 2007; 
Bertolini et al. 2009; Hegadoren et al., 2009). While these peptides are clearly important for 
proper function, classical amino acid (AA) transmitters may also play a significant role in POMC 
cell physiology (van den Pol, 2003; Meister, 2007). Previous reports have shown both GABA 
and glutamate release from POMC cells that have formed recurrent synapses in primary culture 
(Hentges et al., 2004, 2009). In addition, electron micrograph data has shown that POMC 
terminals make both symmetric and asymmetric synapses, suggesting both GABAergic and 
glutamatergic POMC terminals, respectively (Wang et al., 2001; Reyes et al., 2006). However, 
glutamate release from POMC neurons in an intact circuit has not been demonstrated and some 
studies have failed to detect GABAergic markers in POMC neurons using immunohistochemical 
or transgenic approaches (Ovesjö et al., 2001; Vong et al., 2011). A complete understanding of 
how POMC neurons affect the larger circuitry and behavior requires knowing the amino acid 
phenotype of these neurons. Thus, the present study was designed to determine whether POMC 




To examine transmitter release from POMC neuron terminals in an intact system, a 
combined optogenetics-electrophysiology approach was used. This approach is similar to that 
proposed for circuit mapping and functional studies (Petreanu et al., 2007; Atasoy et al., 2008; 
Kohl et al., 2011). Cell type-specific expression of the light-gated ion channel channelrhodopsin-
2 (ChR2) in POMC cells was used to excite POMC neurons as a population with light while 
recording from downstream neurons in slice preparations. With this method, amino acid (AA) 
transmitter release could be observed through native connections. The results show that both 
GABA and glutamate are released from POMC neurons onto downstream cells within the 
arcuate nucleus (ARC), indicating not only the phenotype of AA transmitter release, but also that 
POMC cells can terminate within the ARC. In addition, evoked transmitter currents could be 
dynamically modulated through G-coupled protein receptor (GPCR) activation, suggesting 
physiological regulation of GABA and glutamate release from POMC neurons may be another 
regulatory component of the POMC neuron system. 
 
2.3 Materials and Methods 
Animals 
 Male and female transgenic mice expressing Cre recombinase specifically in POMC cells 
(POMC-Cre) were used for all experiments. Transgenic animals were produced by standard 
techniques (see Xu et al., 2005) and backcrossed >12 generations onto the C57Bl/6 strain. 
Animals were 10-12-weeks-old when electrophysiological experiments were conducted. Mice 
were housed under controlled temperature (22-24°C) and a constant 12 hr light/dark cycle. Mice 
were fed standard rodent chow and tap water ad libitum. All experiments met United States  
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Public Health Service guidelines with the approval of the Colorado State University Institutional 
Animal Care and Use Committee. 
 
Viral gene transfer in vivo 
POMC-Cre transgenic mice (eight-weeks-old) were anesthetized with isoflurane and 
placed in a stereotaxic frame (Kopf Instruments). A viral vector containing a floxed sequence for 
ChR2 with an mCherry tag (AAV2/9.EF1.dflox.hChR2(H134R)–mCherry.WPRE.hGH; 
obtained from the Penn Vector Core at the University of Pennsylvania School of Medicine, 
Philadelphia, Pennsylvania) was unilaterally injected into the ARC of POMC-Cre mice. For each 
animal, a 300 nl injection (3.52E+12 GC/ml) was made using a Hamilton syringe and the 
following coordinates from bregma: X, -0.27 mm; Y, -1.35 mm; Z, -6.14 mm. After 
microinjection, the wound was sutured and animals were left to recover for a minimum of 14, but 
no longer than 28 days before experiments to ensure a high level of ChR2 expression. 
 
Immunofluorescence 
18 days post-AAV injection, mice were anesthetized, perfused transcardially with 4% 
paraformaldehyde, and brains were removed and post-fixed as described previously (Hentges et 
al., 2009). Sagittal brain slices (50 µm) containing the ARC were prepared on a vibratome and 
were subsequently incubated in phosphate-buffered saline (PBS) with 3% normal goat serum and 
0.3% Triton-X-100. The POMC peptide adrenocorticotropin (ACTH) was detected using a rabbit 
anti-ratACTH primary antibody (National Hormone and Peptide Program; 1:10,000, overnight at 
4°C). Tissue was then washed in PBS and incubated with an Alexa Fluor 647-conjugated donkey 
anti-rabbit secondary antibody (Invitrogen; 1:400). ACTH-immunoreactivity was visualized 
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using a Zeiss-510-Meta laser-scanning confocal microscope based on the far-red fluor (633 nm 
excitation and 650 nm emission wavelengths) and ChR2-mCherry was visualized using 580 nm 
excitation and 600 nm emission filters. Colocalization of ACTH immunoreactivity and ChR2-
mCherry expression was determined by counting the labeled cells in sections from 2 brains. Two 
investigators made independent counts of labeled cells in each brain to verify the results. 
 
Electrophysiology 
Sagittal brain slices containing the ARC were prepared as previously described (Pennock 
and Hentges, 2011). Whole-cell voltage clamp recordings were made at a temperature of 37°C 
with an internal recording solution containing the following (in mM): 57.5 KCl, 57.5 K-methyl 
sulfate, 20 NaCl, 1.5 MgCl2, 5 Hepes, 0.1 EGTA, 2 ATP, 0.5 GTP, 10 phosphocreatine, pH 7.3. 
Recording pipettes had a tip resistance of 1.5-2.2 MΩ when filled with internal solution. Slices 
were maintained in artificial cerebrospinal fluid (aCSF) containing the following (in mM): 126 
NaCl, 2.5 KCl, 1.2 MgCl2, 2.4 CaCl2, 1.2 NaH2PO4, 21.4 NaHCO3, and 11.1 glucose (saturated 
with 95% O2 and 5% CO2). Whole-cell recordings were conducted through the use of an 
Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA) and data was collected using 
AxographX software (Axograph, Sydney, Australia) running on a Mac OS X operating system. 
POMC neurons expressing ChR2 were identified by the mCherry fluorophore expressed as a 
fusion protein on the channel. Cells were held at -60 mV for recording light-evoked postsynaptic 
currents (PSCs). When recording from unidentified cells within the ARC, the patched cells were 
within ~100 μm of POMC-ChR2 expressing cells. Cells were excluded if the access resistance 
increased significantly from the initial access (6.04 ± 1.17 MΩ for unidentified cells, 4.6 ± 0.75 
MΩ for ChR2-expressing POMC neurons, and 4.9 ± 0.71 MΩ for POMC neurons without 
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ChR2). Postsynaptic currents were evoked using either a 25 or 100 ms blue light pulse delivered 
every 20 s to the slice from a mercury light source with a rapid shutter system (Lumen Pro 200, 
Prior). The light was adjusted to the minimum intensity required to evoke a consistent PSC, 
which was generally between 5-11 mW/mm2. PSCs were evoked for at least 5 min under 
baseline conditions to ensure a steady recording. PSCs were collected at 10kHz and digitally 
filtered at 1kHz. Data were analyzed by comparing an average of 3 min of baseline to an average 
of 2 min of steady-state response to drug. Excitatory and inhibitory PSCs were identified 
pharmacologically by blocking GABAA-mediated currents with bicuculline methiodide (BMI, 10 
µM; Tocris) or AMPA- and NMDA-mediated currents with 6,7-dinitroquinoxaline-2,3(1H,4H) 
(DNQX, 10µM; Sigma) and (+)-MK-801 (15 µM;Sigma). Representative recordings were 
plotted by minute, averaging the peak amplitude of 3 sweeps spaced 20 seconds apart. 
 
Drugs 
Stock solutions of DNQX, (+)-MK-801, and (+)-(5α,7α,8β)-N-methyl-N-[7-(1-
pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benzeneacetamide (U69593; Biomol International) were 
prepared with DMSO at least 10,000x more concentrated than the final solution. Stock solutions 
of [D-Ala2, N-Me-Phe4, Gly5-ol]-enkephalin (DAMGO; Sigma), D-Phe-Cys-Tyr-D-Trp-Arg-
Thr-Pen-Thr-NH2 (CTAP; Tocris Bioscience), nor-binaltorphimine (nor-BNI; Sigma), [D-
Pen2,5]enkephalin (DPDPE; Bachem), bicuculline (Tocris Bioscience), [Met5]enkephalin 
(Sigma), baclofen (Sigma), dynorphin A (Tocris Bioscience), naloxone (Sigma), (2S)-3-[[(1S)-1-
(3,4-Dichlorophenyl)ethyl]amino-2-hydroxypropyl](phenylmethyl)phosphinic acid (CGP 55845; 
Tocris Bioscience), and BMI were prepared with distilled water. All drugs were diluted to  
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working concentrations in aCSF and applied via bath perfusion except (+)-MK-801, which was 
applied to the collected slices prior to being moved to the recording chamber. 
 
Data Analysis 
All data are presented as mean ± SEM. Comparisons between groups were compared 
using t-tests. P < 0.05 was considered a significant difference. 
 
2.4 Results 
Functional expression of ChR2 in POMC cells  
The selective expression of ChR2 in POMC neurons was verified in slices prepared from 
POMC-Cre mice that had been injected with the viral vector containing the floxed ChR2-
mCherry ≥2 weeks earlier. Approximately 88% of cells expressing ChR2-mCherry also 
displayed ACTH-immunoreactivity (ACTH-IR). Cells expressing mCherry without detectable 
ACTH-IR most likely represent POMC neurons with low ACTH expression. Injection of the 
viral vector into the ARC of wild-type C57Bl/6 mice yielded no detectable mCherry 
fluorescence (data not shown), indicating that expression is limited to cells that express Cre 
recombinase. Approximately 79% of ACTH-IR cells in the injected side of the ARC expressed 
mCherry (Figure 2.1A). ChR2-mCherry was notable throughout the membranes of cell body and 
neuronal projections, indicating strong expression and widespread trafficking of the channel. 
These findings indicate specific targeting of strong ChR2 expression to POMC neurons. 
Individual cells expressing high amounts of ChR2-mCherry were easily detected in live 
brain slices prepared from injected mice (Figure 2.1B). POMC cells with ChR2 had similar basal 










Figure 2.1. POMC cell-specific expression of functional ChR2. (A) Confocal z-stack image of a 
brain slice containing cells expressing ChR2-mCherry 18 days after AAV injection (left panel) and 
cells immunoreactive for ACTH (center panel). A high degree of colocalization can been seen in 
the merged image (right panel). (B) Images of the hypothalamus in a live brain slice from an AAV 
injected mouse shown in DIC (top panel) and fluorescence (bottom panel). Arrow indicates a 
neuron with a high level of ChR2 expression within the focal plane. (C) Whole cell currents from a 
ChR2-expressing neuron elicited by pulses of blue light at increasing intensities (0 at top trace; 28 
mW/mm2 elicited the largest current, bottom-most trace). (D) Light-induced depolarization of a 
ChR2-expressing neuron caused action potential firing in current clamp recordings. 
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1.3 ± 0.1 GΩ in ChR2 positive cells versus 1.6 ± 0.2 GΩ in ChR2 negative POMC neurons (n = 
9, p = 0.31). Whole-cell capacitance was also not different between ChR2 expressing and non-
expressing POMC neurons (29 ± 2.6 pF and 25.5 ± 1.4 pF, respectively; n = 9, p = 0.24). Whole-
cell voltage clamp recordings made in POMC-ChR2 neurons indicate that ChR2 mediates an 
inward current in response to blue light (~ 470 nm, Figure 2.1C). Peak and steady-state current 
responses were stereotypical of currents mediated by ChR2(H134R) (Lin et al., 2009). In current 
clamp, blue light depolarized POMC-ChR2 neurons and caused action potential firing (Figure 
2.1D). 
 
GABA and glutamate release from POMC neurons 
Activation of POMC neurons via ChR2 was used to determine if POMC cells release the AA 
transmitters glutamate and/or GABA in an intact neuronal network. Whole-cell voltage clamp 
recordings were made in unidentified cells (not expressing detectable mCherry) in the ARC near 
POMC neurons. The unidentified cells had basal properties similar to POMC neurons (input 
resistance, 1.1 ± 0.15 GΩ, capacitance, 23.3 ± 1.54 pF; n = 15, p > 0.05 for both properties 
compared to POMC neurons with or without ChR2). The likelihood that a pulse of light evoked 
neurotransmitter release from POMC-ChR2 cells varied from 50% to 8.33% (e.g. 1 out of 12 
cells patched) depending on the accuracy of the injection and thus, the number of ChR2-
expressing neurons. When light pulses evoked transmitter release from POMC terminals, the 
currents in the postsynaptic cell were mediated by both GABAA and AMPA receptors, indicating 
GABA and glutamate release from POMC neurons. Light-evoked inhibitory postsynaptic 
currents (IPSCs) were recorded in the presence of the AMPA receptor blocker DNQX (10 μM, 
Figure 2.2Ai) and were completely inhibited by the GABAA receptor antagonist BMI (10 μM, 
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Figure 2.2Aii). Upon washout of BMI, the current returned (Figure 2.2Aiii). Reversing the order 
of antagonist application showed the glutamatergic nature of some light-evoked currents. 
Currents evoked in the presence of BMI (Figure 2.2Bi) were blocked by the addition of DNQX 
to the bath (Figure 2.2Bii) and returned upon washout of DNQX (Figure 2.2Biii). In the presence 
of BMI, the onset of evoked currents was often substantially delayed from the initial light 
stimulus (as seen in Figure 2.2B), which may indicate a polysynaptic response. However, direct 
innervation was indicated in some instances, including where a brief light pulse evoked PSCs 
that were abolished only when both GABAA and AMPA receptors were blocked (Figure 2.2Ci-
iv). Altogether, when a light-evoked PSC was detected in a non-POMC cell, it was most often 
GABAergic in nature (27/39 cells showed GABA-mediated PSCs, Figure 2.2D). Glutamate-
mediated PSCs accounted for 23% of the PSCs observed (9/39 PSCs), and 3 cells appeared to 
receive input from both GABAergic and glutamatergic POMC cells (Figure 2.2D), although the 
possibility that individual terminals may release both GABA and glutamate cannot be ruled out 
based on the present experiments.   
The majority of light-evoked PSC recordings were made in non-POMC neurons, since 
the direct inward current carried through ChR2 can obscure the current induced by GABA or 
glutamate release. However, some POMC cells expressing ChR2 displayed both a direct ChR2-
mediated inward current and a slightly delayed light-evoked GABA-mediated IPSC (n = 4, 
Figure 2.2E). This result indicates that POMC neurons can innervate one another.         
All light-evoked currents in cells downstream of POMC neurons could be completely 
blocked by BMI and/or DNQX indicating that GABA and glutamate were the only transmitters 
being released in response to the acute depolarization of POMC neurons. The light-evoked 




Figure 2.2. POMC neurons release GABA and glutamate onto cells within the arcuate nucleus. Light-
evoked IPSCs observed in the presence of DNQX (10 μM, Ai) were abolished with the addition of BMI (10 μM, 
Aii). Light evoked EPSCs observed in the presence of BMI (Bi) were abolished with the addition of DNQX 
(Bii). (C) An example of a cell with light-evoked IPSCs and EPSCs. Upon washout of DNQX and/or BMI 
evoked currents returned (Aiii, Biii, Civ). Panels in A and B consist of three overlayed sweeps, whereas panels 
in C are each an average of three sweeps. The transmitter(s) mediating evoked currents was determined in all 
cases where a PSC was observed and is presented in (D). (E) A light-evoked IPSC in a POMC cell which also 
displays a direct ChR2 current (top trace). The evoked IPSC is ablated by BMI (bottom trace). (F) Currents 
evoked onto an unidentified cell are completely inhibited by treatment with TTX (1 µM). 
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propagation and not direct stimulation of terminal release based on the observation that the 
addition of tetrodotoxin (TTX, 1 µM) completely abolished light-evoked PSCs (98.68 ± 0.94% 
reduction, n = 4, p < 0.001; Figure 2.2F). 
 
Opioids inhibit neurotransmitter release from POMC terminals via mu and kappa receptors  
 The ability of opioid receptor agonists to modulate the release of GABA and glutamate 
from POMC terminals was evaluated, since opioids reliably inhibit AA transmitter release from 
unidentified terminals within the ARC (Emmerson and Miller, 1999; Pennock and Hentges, 
2011). The mu (MOR) and delta opioid receptor (DOR) agonist ME (10 µM) caused a dramatic 
decrease in light-evoked IPSCs (72.46 ± 4.00% reduction, n = 9, p < 0.001; Figure 2.3A-B) and 
EPSCs (72.45 ± 4.64% reduction, n = 4, p < 0.001; Figure 2.3C-D). This reduction in current 
was readily reversed by washing out of drug (103.73 ± 10.03% of baseline, n = 5, p = 0.73; 
Figure 2.3C) or by co-applying the MOR-selective antagonist, CTAP (500 nM, 97.22 ± 9.42% of 
baseline, n = 8, p = 0.74; Figure 2.3A). 
The DOR selective agonist DPDPE (100 nM) had no effect on PSC amplitude in any cell 
tested (100.12 ± 3.41% of baseline, n = 4, p = 0.49), whereas the MOR selective agonist 
DAMGO (10 µM) reliably inhibited IPSC amplitude (72.70 ± 7.80% reduction, n = 4, p = 0.001; 
Figure 2.4A,B). The inhibition was reversed by CTAP (500 nM, 88.65 ± 5.95% of baseline, n = 
4, p = 0.15; Figure 2.4A). Thus, mu but not delta receptor agonists can inhibit AA transmitter 
release from POMC neurons. Kappa opioid receptor (KOR) agonists inhibit IPSCs regulating 
POMC neurons (Pennock and Hentges, 2011). Although POMC neurons are not directly 
hyperpolarized by KOR activation (Pennock and Hentges, 2011), the possibility that POMC 
neurons express KORs presynaptically to inhibit transmitter release was examined. The KOR 
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selective agonist U69593 (500 nM) inhibited light-evoked IPSCs in unidentified downstream 
neurons (63.39 ± 8.33% reduction, n = 6, p < 0.001) and the KOR antagonist Nor-BNI (100 nM) 
reversed the inhibition (95.68 ± 8.57% of baseline, n = 6, p = 0.64; Figure 2.4C-D). Thus, KORs 
expressed in POMC neurons inhibit AA release from POMC neurons even though they do not 





Figure 2.3. Light-evoked IPSCs and EPSCs are inhibited by opioid receptor activation. (A) Plot of 
light-evoked IPSC amplitudes over time shows an inhibition of light-evoked IPSCs by the nonspecific 
opioid agonist ME (10 μM). The IPSC inhibition is reversed by application of the MOR-selective 
antagonist, CTAP (500 nM). (B) Representative traces of IPSCs in control conditions and in the presence of 
ME. (C) ME inhibits light-evoked EPSC amplitude and EPSC amplitude returns to baseline upon washout 
of ME. (D) Representative traces of EPSCs in control conditions and in the presence of ME. The 





























GABAB receptor activation inhibits transmitter release from POMC cells 
In addition to opioid receptors, GABAB receptors can inhibit transmitter release from 
unidentified terminals in the ARC. To determine if GABAB receptors could modulate transmitter 
release from POMC neuron terminals in particular, light-evoked release was monitored in the 
presence of the GABAB receptor agonist baclofen. Baclofen (30 µM) caused a significant 
inhibition of light-evoked IPSCs in neurons downstream of POMC-ChR2 neurons (89.04 ± 
3.20% reduction, n = 6, p < 0.001; Figure 2.5A-B). In 4 cells, baclofen (30 µM) completely 
 
Figure 2.4. Mu and kappa opioid receptors mediate inhibition of evoked release from POMC terminals. 
(A) Plot of light-evoked IPSC amplitudes over time shows no effect of the DOR-selective agonist, DPDPE (100 
nM) and inhibition of IPSC amplitude by the MOR-selective agonist, DAMGO (10 μM). The DAMGO-induced 
inhibition is reversed by application of the MOR-specific antagonist, CTAP (500 nM). (B) Representative traces 
taken during control and agonist treatment. (C) The specific KOR agonist U69593 (500 nM) inhibited evoked 
IPSC amplitude and was reversed by the addition of nor-BNI (100 nM). (D) Representative traces taken during 
control conditions and during U69593 treatment. 
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ablated the light-evoked IPSC. Baclofen-
induced inhibition of the IPSC was fully 
reversed by washout or by co-applying the 
GABAB receptor antagonist CGP 55845 (1 
µM, 92.44 ± 4.19% of baseline, n = 6, p = 
0.13). This result indicates that POMC 
neurons express GABAB receptors, and 
these receptors can inhibit presynaptic 









The results of the present study show that POMC neurons are not only peptidergic, but 
release the classical amino acid transmitters GABA and glutamate. Considerable release of these 
transmitters occurs within the ARC and can be modulated dynamically by agents such as opioids 
and GABA. Although GABAergic and glutamatergic phenotypes had previously been suggested 
for POMC neurons based on immunolabeling and studies of transmitter release from cultured 
POMC neurons (Hentges et al., 2004, 2009; Meister, 2007), the finding that GABA and 
Figure 2.5. GABA-B receptor activation inhibits GABA 
release from POMC terminals. (A) Light-evoked IPSC 
amplitudes are inhibited by baclofen (30 μM). The 
inhibition is reversed by washout of drug. (B) 
Representative traces taken during control conditions and 
during baclofen treatment. 
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glutamate release can be evoked from POMC cells in live brain slices indicates that theses 
transmitters are likely to play an important role in the intact circuitry.  
 
Advantages of the optogenetic approach 
 The difficulty of determining transmitter phenotype in hypothalamic neurons using 
traditional means stems from 1) the fact that this structure lacks lamination precluding the use of 
paired recordings to detect released transmitters, and 2) the inability to directly detect GABA and 
glutamate reliably using immunohistochemical methods in this tightly-packed heterogeneous 
brain region. The optogenetic approach used in the present study allows for the activation of an 
entire population of identified neurons, which greatly increases the likelihood of detecting 
transmitter release onto downstream target neurons. Using this approach, Atasoy et al. (2008) 
recently demonstrated that POMC neurons could release GABA onto neurons in the 
paraventricular nucleus. The present data show that POMC neurons can also release glutamate, 
and that these neurons release both inhibitory and excitatory AA transmitters onto neurons 
within the arcuate nucleus. Thus, optogenetic activation of POMC neurons is a useful means of 
mapping distal projections and studying local innervation. 
 The use of combined optogenetic activation and electrophysiologic recording to detect 
transmitter release has many advantages over immunodetection and marker-based methods, 
including increased sensitivity and real-time assessment of release. Based on various labeling 
approaches, the AA phenotype of POMC neurons had been disputable. The inability to detect 
GABA immunoreactivity in POMC neurons (Ovesjö et al., 2001), and the presence of 
glutamatergic markers in a small population of POMC neurons (Collin et al., 2003; Kiss et al., 
2005) suggested that POMC neurons are not GABAergic. However, when the GAD67 promoter 
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was used to drive expression of the green fluorescent protein in transgenic mice, labeling could 
be observed in a subpopulation of POMC neurons (Hentges et al., 2004; Yee et al., 2009), 
suggesting that some POMC neurons may be GABAergic. In addition, approximately one-third 
of POMC neurons express GAD mRNA (Hentges et al., 2004). The GABAergic nature of some 
POMC neurons was further indicated in studies showing evoked GABA release from POMC 
neurons in primary cultures (Hentges et al., 2004, 2009). Despite the evidence suggesting that 
POMC neurons can be either GABAergic or glutamatergic based on phenotypic markers and 
GABA and glutatmate release from cultured POMC neurons (Hentges et al., 2009), the ability of 
these neurons to release both transmitters in brain slices had not been demonstrated until the 
present study.  
 Interestingly, although the present data clearly show evoked GABA release from POMC 
terminals, a recent study failed to detect vesicular GABA transporter (vGAT) in POMC neurons 
(Vong et al., 2011). This transporter is the only protein identified to date that packages inhibitory 
transmitters into vesicles (McIntire et al., 1997; Sagne et al., 1997; Gasnier, 2004). Whether the 
apparent lack of vGAT expression in POMC neurons is due to the transgenic expression system 
used, or reflects that very low levels of vGAT are sufficient to package GABA in POMC 
neurons remains to be determined. Nonetheless, the expression of GAD67-gfp and GAD mRNA 
in POMC neurons, as well as the release of GABA from POMC neurons in culture and in brain 
slices indicate that at least a subpopulation of POMC neurons is indeed GABAergic. Further 
studies are needed to determine whether POMC neurons release GABA in a vGAT-independent 
manner or if vGAT expression is too low to be readily detected. Either way, vGAT may not a 
reliable indicator of the GABAergic nature of POMC neurons.   
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GABA and glutamate release from POMC neurons is consistent with synaptic morphology 
 The present data localize a portion of POMC cell AA transmitter release to the ARC. The 
release of GABA is consistent with ultrastructural studies demonstrating POMC terminals make 
symmetrical (GABAergic) synapses onto neurons within the ARC (Chen and Pelletier 1983; 
Kiss and Williams, 1983). Asymmetrical (glutamatergic) POMC synapses within the ARC have 
not been described, although glutamate release was detected locally in the present study. The low 
percentage of PSCs that were mediated by glutamate and the relatively low number of POMC 
neurons expressing vGLUT2 (Vong et al., 2011) may explain why, morphologically, 
glutamatergic POMC terminals have not been observed in the ARC. Interestingly, POMC 
neurons have been shown to form both symmetrical and asymmetrical synapses onto neurons in 
distal target sites including the dorsal raphe nucleus (Wang et al., 2001) and the locus coeruleus 
(Reyes, et al., 2006). Thus, GABA and glutamate release from POMC neurons may be important 
for regulation both locally and at distal target sites. 
 
Amino acid transmitters and energy homeostasis 
  The studies of AA transmitters in hypothalamic circuits to date indicate a significant 
contribution of these transmitters in the regulation of food intake and metabolism. For example, 
glutamate release from neurons in the ventromedial hypothalamus is an important step in 
preventing hypoglycemia (Tong et al., 2007), the release of GABA from NPY/AGRP neurons in 
the ARC is also required for the normal regulation of energy balance (Tong et al., 2008), and 
GABA release from NPY/AGRP neurons into the parabrachial nucleus prevents starvation (Wu 
et al., 2009). It is likely that AA transmitters from POMC cells have important analogous 
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functions, although perhaps with more diversity, given the release of both GABA and glutamate 
from POMC neurons. 
 
Presynaptic regulation of transmitter release 
  In the present study, the ability of GABAB and opioid receptor agonists to regulate AA 
transmitter release from POMC neurons was demonstrated. These studies were undertaken 
primarily to determine if AA release from POMC neurons could be dynamically modulated as 
would be expected if these transmitters play an important regulatory role. GABAB and opioid 
receptors were chosen, as both have been shown to potently modulate transmitter release from 
terminals within the hypothalamus (Mouginot et al., 1998; Emmerson and Miller, 1999; Pennock 
and Hentges, 2011). Since transmitter release was evoked only from POMC neurons and 
inhibited by GABAB, MOR, and KORs, it is now clear that these receptors can inhibit release 
specifically from POMC terminals. The results raise the possibility that GABA and/or opioids 




The data collected here show that POMC neurons are not only peptidergic, but release the 
classical amino acid transmitters GABA and glutamate. Release of these transmitters can be 
dynamically modulated by agents such as opioids and GABA. Thus, in addition to the roles 




3. Gad1 mRNA AS A RELIABLE INDICATOR OF ALTERED GABA RELEASE FROM 




The strength of GABA-mediated inhibitory synaptic input is a principle determinant of 
neuronal activity. However, because of differences in the number of GABA afferent inputs and 
the sites of synapses it is difficult to directly assay for altered GABA transmission between 
specific cells. The present study tested the hypothesis that the level of mRNA for the GABA 
synthetic enzyme glutamate decarboxylase (GAD) can provide a reliable proxy for GABA 
release. This was tested in a mouse hypothalamic circuit important in the regulation of energy 
balance. Fluorescent in situ hybridization results show that the expression of Gad1 mRNA 
(encoding the GAD67 enzyme) was increased in hypothalamic neuropeptide Y/agouti related 
peptide (NPY/AgRP) neurons after an overnight fast, consistent with the ability of GABA from 
these neurons to stimulate food intake. Optogenetic studies confirmed that the observed increase 
in Gad1 mRNA correlated with an increase in the probability of GABA release from NPY/AgRP 
neurons onto downstream proopiomelanocortin neurons. Likewise, there was an increase in the 
readily releasable pool of GABA in NPY/AgRP neurons. Selective inhibition of GAD activity in 
NPY/AgRP neurons decreased GABA release, indicating that GAD67 activity, which is largely 
dictated by expression level, is a key determinant of GABA release. Altogether, it appears that 
Gad expression may be a reliable proxy of altered GABAergic transmission. Examining changes 
in Gad mRNA as a proxy for GABA release may be particularly helpful when the downstream 
                                                 
2 Full article from Dicken MS, Hughes AR, and Hentges ST. (2015) European Journal of Neuroscience, 42(9):2644-
53. Shane Hentges contributed to experimental design, performed in situ hybridization, and contributed to writing of 
the manuscript. Alex Hughes performed in situ hybridization and edited the manuscript. Matthew Dicken 
contributed to experimental design, performed electrophysiology experiments, analyzed collected data, and 
contributed to writing of the manuscript. 
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The amino acid transmitter GABA has long been recognized as a critical mediator of 
neuronal inhibition, yet the role of GABA in several circuits is just beginning to be explored in 
detail. For example, despite the fact that GABA was first detected in neuropeptide Y/agouti-
related peptide (NPY/AgRP) neurons of the hypothalamus nearly 2 decades ago (Horvath et al., 
1997), it has only recently been discovered that synaptic GABA released from these neurons 
acutely stimulates food intake independent of peptide release (Tong et al., 2008; Wu et al., 2008; 
Krashes et al., 2013). The dynamic regulation of GABA release from this population of cells, 
particularly in response to altered energy state has not yet been explored. Several factors, such as 
sparse and spatially restricted afferent inputs and a potential lack of tools to detect transmitter 
release, hinder the ability to detect altered GABAergic transmission in various neuronal circuits. 
Therefore, the present study aimed to determine if the expression of GABA neuron specific 
mRNA could serve as a proxy for altered GABAergic transmission.  
Several proteins are only found in neurons that can package and release GABA, including 
the vesicular GABA transporter (vGAT), the plasma membrane GABA transporters (GATs), and 
GABA synthetic enzymes glutamate decarboxylase (GAD) 65 and 67. While vGAT is generally 
necessary for vesicular packaging and release of GABA, several lines of evidence suggest that 
modest changes in vGAT expression will not affect GABA release (Edwards, 2007; Apostolides 
& Trussell, 2013). Indeed, heterozygous mice with a significant reduction in vGAT expression 
show no apparent changes in synaptic GABA release (Yamada et al., 2012). By contrast, the 
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levels of cytosolic GABA, which are derived primarily from glutamate uptake (Mathews & 
Diamond, 2003), greatly affect vesicular GABA content and synaptic strength (Apostolides & 
Trussell, 2013; Ishibashi et al., 2013; Wang et al., 2013). Cytosolic GABA content is largely 
controlled at the level of glutamate decarboxylation by the GAD enzymes, with GAD67 being 
responsible for >90% of brain GABA content and essential for synaptic GABA release and 
survival (Asada et al., 1997; Chattopadhyaya et al., 2007; Obata et al., 2008; Lazarus et al., 
2013). The necessary nature of GAD67, and the fact that GAD67 protein and its mRNA (Gad1) 
levels are often more sensitive to a number of experimental conditions compared to GAD65 
(Rimvall & Martin, 1992; 1994; McCarthy, 1995; Bowers et al., 1998; Mason et al., 2001), led to 
the current hypothesis that changes in Gad1 expression could provide a means to assess overall 
changes in GABA transmission from a specific neuron type in response to a physiologic 
challenge. The results show that changes in energy state are sufficient to selectively increase or 
decrease Gad1 mRNA in NPY/AgRP neurons and cause a concomitant change in synaptic 
GABA transmission from these neurons. Using Gad1 mRNA as a proxy for altered GABA 
release has the advantages of examining the whole population of neurons at once and does not 
require recording inhibitory postsynaptic currents (IPSCs) from the postsynaptic neuron. 
 
3.3 Materials and Methods 
Animals 
POMC-EGFP (C57BL/6J-Tg(Pomc-EGFP)1Low/J, stock 009593), NPY-hrGFP 
(B6.FVB-Tg(Npy-hrGFP)1Lowl, stock 006417), and AgRP-Cre mice (AgRPtm1(cre)Lowl, stock 
012899) were obtained from The Jackson Laboratory. POMC-DsRed animals (Hentges et al., 
2009) were originally obtained from Dr. Malcolm Low. In the arcuate nucleus, NPY expression 
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is restricted to cells that also express AgRP with overlap greater than 90% (Hahn et al., 1998), 
thus the transgenically-expressed NPY-hrGFP specifically labels cells also expressing AgRP in 
this region. All transgenic animals were maintained on the C57BL/6J background. Both male 
and female mice (8-12 weeks old) were used for experiments and were distributed evenly over 
treatment conditions. Mice were maintained on a 12-hour light/dark cycle and were given ad 
libitum access to water and standard rodent chow unless noted otherwise. All experimental 
protocols were reviewed and approved by the Colorado State University Institutional Animal 
Care and Use Committee and were in accordance with the United States Public Health Service 
guidelines for animal use. 
 
In situ hybridization 
NPY-hrGFP mice were deeply anesthetized with sodium pentobarbital and transcardially 
perfused with a 10% sucrose solution, followed by 4% paraformaldehyde in PBS. Brains were 
post-fixed overnight at 4°C in 4% paraformaldehyde solution in PBS. 50 µm sections containing 
the arcuate nucleus were cut on a vibratome, collected in cold PBS and processed for in situ 
hybridization to detect Gad1 or Gad2 mRNA as detailed previously (Jarvie & Hentges, 2012). 
The fluorescent signal of the hrGFP was quenched through the in situ hybridization procedure. 
Therefore, after completion of the in situ hybridization protocol, immunofluorescence was used 
to detect hrGFP by addition of a polyclonal antibody against hrGFP (1:1000, Agilent 
Technologies, Santa Clara, CA) overnight at 4°C and detection with goat anti-rabbit conjugated 
to Alexa 568 (1:400, 1 h room temperature). Confocal images were collected using a Zeiss 510-
Meta confocal microscope. Z-stacks were initially constructed with 5-9 images 3 µm apart in 
depth for all tissue sections containing cells labeled for hrGFP. These stacks were pared down to 
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4 sequential images for analysis. Cell counts were made using a modification of the 3D counting 
method described by Williams and Rakic (1988) to limit oversampling (Williams & Rakic, 
1988). Only gfp-positive cells with a clear nucleus and completely contained in a 300 x 300 x 
12-µm counting box on the x-y-z plane were counted and the presence or absence of Gad1 signal 
was determined for each gfp-positive cell. Average fluorescence intensity had to be greater than 
10% above background for a cell to be considered positive for either signal and for Gad1, the 
signal had to be constrained within the somatic region of a gfp-positive cell for that gfp cell to be 
considered as expressing the Gad1 signal. All images were analyzed using NIH ImageJ by an 
experimenter blinded to the treatment groups. NPY-hrGFP-positive cells were identified in a 
minimum of 7 slices per animal. For each hrGFP-positive cell, the assessor determined whether 
or not the cell also contained the Gad label while examining individual images from the image 
stack and label intensity was automatically determined for each cell.  
 
In vivo gene delivery via adeno-associated virus 
Adeno-associated virus (AAV) (3.56E+13 GC/ml) containing a double-floxed sequence 
for ChR2 with an mCherry tag (AAV2/9.EF1.dflox.hChR2(H134R)– mCherry.WPRE.hGH; 
obtained from the Penn Vector Core at the University of Pennsylvania School of Medicine, 
Philadelphia, Pennsylvania) was delivered bilaterally into the arcuate nucleus as previously 
described (38) and recordings were made 2-3 weeks post-injection.  
 
Brain slice collection and electrophysiology 
Sagittal brain slices (240 µm) containing the arcuate nucleus were prepared as previously 
described (Pennock & Hentges, 2011). Optogenetic stimulation and electrophysiologic 
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recordings were performed as previously described (Dicken et al., 2012). In brief, slices were 
maintained at 37°C in artificial cerebrospinal fluid (aCSF) containing the following (in mM): 
126 NaCl, 2.5 KCl, 1.2 MgCl2, 2.4 CaCl2, 1.2 NaH2PO4, 21.4 NaHCO3, and 11.1 glucose 
(saturated with 95% O2 and 5% CO2). Immediately after collection, slices were maintained in 
aCSF containing the NMDA receptor blocker MK-801 (15 µM) for at least 45 min before being 
transferred to the recording chamber. Whole-cell voltage clamp recordings were made with an 
internal recording solution containing the following (in mM): 57.5 KCl, 57.5 K-methyl sulfate, 
20 NaCl, 1.5 MgCl2, 5 Hepes, 0.1 EGTA, 2 ATP, 0.5 GTP, 10 phosphocreatine, pH 7.3. 
Recording pipettes had a tip resistance of 1.5–2.2 MΩ when filled with internal solution. For 
cell-attached recordings, the recording electrode contained aCSF. AgRP cells were identified by 
the fluorescence of the mCherry tag fused to ChR2. POMC cells were identified by EGFP 
fluorescence. Cells selected for patching were in the region containing mCherry positive fibers or 
cell bodies. Recordings were excluded from analysis if access resistance changed significantly 
during the recording or if access resistance increased above 18 MΩ. IPSCs were evoked either 
with paired 2 ms 470 nm light pulses 100 ms apart for paired-pulse ratio (PPR), or by 40 2 ms 
light pulses 100 ms apart for the depletion protocol through the use of an LED/LEDD1B driver 
(Thorlabs, Newton, NJ) connected to a TTL output on the ITC-18 data acquisition board 
(InstruTech, Longmont, CO). For PPR acquisition, sweeps were 20 s apart. A 40 s break between 
sweeps was used in experiments with depletion protocol. In all light-evoked-release studies, the 
light intensity was adjusted to the minimum level that would evoke consistent currents from 
ChR2-expressing cells, and currents were evoked for data collection no sooner than 4 minutes 
after break-in. Recordings were collected at 10kHz, digitally filtered at 1kHz, and at least 3 
consecutive sweeps were averaged for presentation and analysis. To verify that evoked currents 
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were mediated by GABAA receptors, bicuculline methiodide (BMI; 10 μM; R&D Systems, 
Minneapolis, MN) was bath applied to the slice after experiments and always abolished the 
evoked currents. When recording from recurrent synapses in culture, GABA was evoked using a 
2 ms depolarization to 0 mV (action potential artifacts are blanked in averaged traces). 
 
Primary hypothalamic tissue culture 
Tissue culture was performed as previously described (Hentges et al., 2004) from 
hypothalami of young (P2-P7) NPY-hrGFP mice with minor modifications. In brief, 
hypothalami were collected into ice-cold Hibernate-A medium (Life Technologies). Tissue was 
minced, and cells were dissociated after exposure to papain (20 U/ml; Worthington) by passing 
through glass pipettes with fire polished tips. Cells were plated onto glass coverslips pre-coated 
with poly-L-lysine in Neurobasal-A medium (Fisher Scientific) supplemented with B27 (Fisher 
Scientific), 0.4mM L-glutamine, and 1% fetal calf serum. The media were replenished every 3–5 
d. Recordings from these cells occurred between 8-16 days of culture with either chelidonic acid 
alone (1 mM, Sigma) or with GABA (10 mM) included in the normal internal recording solution. 
 
Recombinant mouse intraperitoneal leptin injections 
Purified leptin (National Hormone & Peptide Program) was rehydrated by gentle mixing 
in 15 mM sterile HCl and the pH was adjusted to neutral. Leptin was brought to a final 
concentration of 1000 µg/ml with sterile saline. Mice received either a single intraperitoneal (IP) 





All data are presented as mean ± SEM. Comparisons between two groups were evaluated 
using either t-tests, or in the case of the intensity distribution data, a Kolmogorov-Smirnov test. 
One-way ANOVA analyses followed by Tukey’s HSD were used for comparisons between three 
groups. Repeated measures ANOVA with Dunnett post-hoc tests were used in the autapse 
experiments. For all experiments p < 0.05 was considered significant. Readily releasable pool 




Fasting increases Gad1 mRNA in NPY/AgRP neurons 
Since NPY/AgRP neurons are GABAergic, are activated by fasting (Takahashi & Cone, 
2005; Yang et al., 2011) and may release more GABA in response to fasting (Vong et al., 2011) 
we sought to determine whether Gad1 mRNA also increased in these cells in response to fasting 
as a putative indicator of enhanced GABA transmission. In situ hybridization for Gad1 was 
performed in tissue from NPY-hrGFP mice under fed and fasted (17 h) conditions. Food 
restriction caused a significant increase in the number of NPY-hrGFP immuno-labeled cells that 
were also labeled with the probe for Gad1 mRNA (fasted 1.41 ± 0.10 compared to normalized 
control values, n = 6 mice, p = 0.01 by unpaired t-test; Figure 3.1A-B). Additionally, the 
proportion of NPY/AgRP neurons with strong Gad1 signal was increased in fasted mice 
(Kolmogorov-Smirnov test, p = 7.3*10-21, n = 608 cells in fed, 882 cells in fasted from 6 mice 























Figure 3.1. Gad1 increases in NPY/AgRP cells after an overnight fast. NPY-hrGFP neurons were identified 
by immunoreactivity to hrGFP (A, left column, green) and Gad1 was detected using a cRNA probe (A, middle 
column, red). Insets show an enlarged view of the area within the white box. White arrows point to some NPY-
hrGFP cells containing Gad1. Fasting resulted in a significant increase in the percent of NPY cells expressing 
detectable levels of Gad1 (B), and an increase in the proportion of cells with high levels of Gad1 label intensity 
(C). The overall intensity of Gad1 label in the area adjacent to the hrGFP-labeled cells (circled in D) was not 
changed by energy state (E). Scale bar=100 µm. Data are plotted as mean ± SEM. * = p < 0.05. 
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(fed = 300 ± 16 cells/animal, fasted = 314 ± 20 cells/animal, p = 0.58 by unpaired t-test). To 
determine if Gad1 label intensity was broadly elevated in a majority of arcuate nucleus neurons, 
a large ROI was drawn that included a small number of hr-GFP-positive cells and a large number 
of Gad1 labeled cells that were not hrGFP-positive (Figure 3.1D, region indicated by yellow 
circles). The average intensity above background was not significantly different between groups 
(139.9 ± 7.6% in fed, 127.5 ± 5.0% in fasted, n = 6, p = 0.20 by unpaired t-test; Figure 3.1E). 
Therefore, it appears that the fasting-induced increase in Gad1 is relatively restricted to AgRP 
neurons in the arcuate nucleus, consistent with a previous report that also showed no overall 
difference in Gad1 in the hypothalamic arcuate nucleus in response to fasting (Schwartz et al., 
1993).  
A separate in situ hybridization experiment to detect Gad2 mRNA (encoding GAD65) 
was also performed. While the proportion of NPY/AgRP neurons with strong Gad2 signal was 
increased in fasted mice (Kolmogorov-Smirnov test, p = 4.4*10-18, n = 1299 cells in fed, 1430 
cells in fasted from 4 mice per group), fasting did not significantly increase the number of Gad2-
labeled hrGFP-positive cells (fasted 1.02 ± 0.03 compared to normalized controls, n = 4, p = 
0.41 by unpaired t-test). Thus, it appears that Gad1 expression is more sensitive to changes in 
energy balance compared to Gad2. 
 
Fasting increases IPSCs in POMC neurons 
Next, we wanted to determine whether the increase in Gad1 expression after fasting 
might translate into increased synaptic GABA release from AgRP/NPY neurons. Thus, 
spontaneous IPSCs were recorded in hypothalamic POMC neurons, as POMC neurons are 
heavily innervated by AgRP/NPY cells (Cowley et al., 2001; Atasoy et al., 2012; Newton et al., 
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2013). IPSCs were recorded using a pipette solution containing a high concentration of chloride 
causing GABA-mediated currents to be inward. POMC neurons from slices prepared from fasted 
animals (17 h) had a higher frequency of GABA-mediated IPSCs compared to the frequency in 
control mice with ad libitum access to food (7.3 ± 1.3 Hz in fed, 12.8 ± 1.9 Hz in fasted, n = 9 
cells from 4 fed and 5 fasted animals, p = 0.02 by unpaired t-test; Figure 3.2A-C), consistent 
with a previous report (Vong et al., 2011). There was no significant difference in sIPSC 
amplitude between food-restricted and control mice (45.2 ± 3.6 pA in fed, 53.1 ± 4.2 pA in 
fasted, n = 9 cells from 4 fed and 5 fasted animals, p = 0.17 by unpaired t-test; Figure 3.2D), 
however the sample size may have precluded detecting an increase as other investigators have 




Figure 3.2. Spontaneous GABA release onto POMC cells is increased in fasted animals. 
Representative traces of spontaneous GABA-mediated IPSCs in POMC neurons in tissue from 
fed (A) and fasted (B) mice. Compiled results are shown in the graph (C). Current amplitudes 
were not significantly different between feeding states (D). Data are plotted as mean ± SEM. 
*=p < 0.05. 
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AgRP neuron activation is sufficient to acutely inhibit POMC neurons 
Although POMC neurons are known to be postsynaptic to NPY/AgRP cells, it has been 
suggested that NPY/AgRP terminals do not account for a significant portion of the GABA inputs 
to POMC neurons (Tong et al., 2008). Therefore, the selectivity of functional coupling between 
AgRP and POMC neurons was examined. This was accomplished using specific activation of 
NPY/AgRP neurons with ChR2 expressed in NPY/AgRP cells. Strong expression of ChR2-
mCherry in NPY/AgRP neurons was induced following injection of an AAV containing a Cre 
recombinase-dependent sequence for ChR2-mCherry into the arcuate nucleus of AgRP-Cre 
mice. To estimate the percentage of NPY/AgRP neurons expressing ChR2, NPY-hrGFP; AgRP-
Cre double-transgenic mice were injected with the AAV and the tissue was processed for cell 
counting. Approximately 63% of the NPY-hrGFP cells expressed visible levels of ChR2-
mCherry, whereas ChR2-mCherry was not expressed in NPY-hrGFP negative cells. Thus, the 
AgRP-Cre line provides reliable expression of ChR2-mCherry in AgRP neurons. 
Next, AgRP-Cre mice were crossed to POMC-eGFP transgenic mice and double-
transgenic offspring received injections of the virus containing floxed ChR2-mCherry. The 
mCherry tag on the ChR2 was used to detect NPY/AgRP cells while POMC neurons were 
identified by the presence of eGFP (Figure 3.3A). Light-stimulation of ChR2-expressing neurons 
caused an inward current (Figure 3.3B) and caused evoked IPSCs (latency to onset of 4.6 ± 0.2 
ms) in POMC neurons (81 of 91 cells tested, Figure 3.3C, left). The GABAA antagonist BMI 
completely blocked the evoked IPSC in all cells tested (18/18 cells, Figure 3.3C, right). To 
determine whether the connection between AgRP and POMC neurons was specific or could also 
result from other groups of arcuate nucleus neurons, recordings were made in non-POMC 
neurons (cells lacking eGFP). Only 1 of 16 non-POMC neurons displayed an IPSC in response to 
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To determine whether changing GABA release only from AgRP neurons is sufficient to 
alter the activity of POMC neurons, AgRP neurons were stimulated while measuring the firing of 
POMC neurons. Cell-attached recordings were made with external solution in the recording 
pipette such that the internal Cl- concentration was maintained at physiological levels. Activation 
of AgRP neurons decreased spontaneous action potentials and action currents in POMC neurons 
Figure 3.3. AgRP cells expressing ChR2 reliably release GABA onto POMC cells when stimulated. (A) In 
double transgenic AgRP-Cre;POMC-eGFP mice injected with the ChR2 construct, the POMC cells are 
visualized using the GFP tag (green) and AgRP neurons expressing ChR2 are visualized using the mCherry tag 
(red). A brief flash of blue light (indicated by the blue lines) causes a depolarization of ChR2-expressing cells 
and a stereotypical photocurrent in the AgRP cells (B), and evokes IPSCs in POMC cells (C, left) that are 
completely blocked by the GABAA antagonist bicuculline methiodide (BMI; C, right). In cell-attached voltage-
clamp recording with external solution in the pipette, light-evoked GABA release inhibits POMC cell firing and 
action currents are lost (D). Addition of BMI to the bath prevents the light-evoked inhibition of cell firing (E). 
Scale bar in (A) is 100 µm. 
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(0.006 ± 0.006 and 0.031 ± 0.031 of baseline firing, n = 3 cells from 2 animals, p = 0.01 and 
0.04, respectively; Figure 3.3D). Application of BMI blocked the inhibition (Figure 3.3E). The 
results indicate that GABA release from AgRP neurons causes a profound inhibition of POMC 
neurons consistent with a previous report (Atasoy et al., 2012). 
 
Fasting increases GABA release from NPY/AgRP to POMC neurons 
To determine whether fasting increased the strength of the functional coupling 
specifically from NPY/AgRP to POMC neurons, optogenetic activation of NPY/AgRP neurons 
was examined in slices from fasted animals. The probability of GABA release determined by a 
change in the paired-pulse ratio was examined in slices from fed and fasted animals. Consistent 
with a higher probability of release, the PPR decreased in slices from fasted animals (0.94 ± 0.07 
in fed, 0.75 ± 0.03 in fasted, 0.91 ± 0.06 in re-fed, n = 11 fed, 12 fasted, 11 re-fed cells from 6, 5, 
and 6 animals, respectively, one-way ANOVA, significant with Tukey’s HSD; Figure 3.4A-B). 
Although slightly higher after fasting, the overall amplitude of the first evoked current was not 
significantly different between groups (410.8 ± 56.5 pA in fed, 533.0 ± 88.4 pA in fasted, 431.7 
± 79.2 pA in re-fed, n = 11 fed, 12 fasted, 11 re-fed cells from 6, 5, and 6 animals, respectively, 
one-way ANOVA, not significant with Tukey’s HSD; Figure 3.4C). There was a weak negative 
correlation between PPR and initial IPSC amplitude (r = -0.36, r2 = 0.15, p = 0.02). 
The increase in probability of release could suggest that there is more GABA in the 
terminals overall. To test this possibility, the readily releasable pool (RRP) of GABA was 
examined in slices from fed and fasted animals using a depletion protocol (Schneggenburger et 
al., 1999). Repetitive pulses of light (40 at 10 Hz) were applied to evoke GABA release while 



















Figure 3.4. Fasting increases the probability of release from NPY/AgRP cell terminals presynaptic to 
POMC neurons. Representative traces (average of three consecutive sweeps) of GABA-mediated IPCSs 
light-evoked from NPY/AgRP neuron terminals in ad-lib fed (control, left), overnight fasted (middle), and 
re-fed (right) conditions are shown in (A). The paired-pulse ratio in mice allowed a 3 h re-feeding period 
after fasting is comparable to controls (B). There was not significant difference in peak GABA current 
amplitude between groups (C). Data are plotted as mean ± SEM. * = p < 0.05. 
Figure 3.5. Fasting increases the readily releasable pool of GABA in NPY/AgRP cell terminals. Trains 
of light stimuli (40 stimulations at 10 Hz) were applied to brain slices prepared from fed (A) and fasted (B) 
mice. Cumulative current plots were made and the readily releasable pool was estimated by calculating the 
y-intercept from an extrapolated line drawn through the final 14 points of the plot. Estimated readily 
releasable pool is significantly increased in fasted animals (inset in B). Data are plotted as mean ± SEM. * = 
p < 0.05. 
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and a line was extrapolated from the linear portion of the curve and the Y-intercept was used to 
determine the RRP (Figure 3.5A-B, plotted data). A significantly higher RRP was observed in 
slices from fasted animals (1.4 ± 0.32 nA in fed, 2.5 ± 0.45 nA in fasted, n = 13 fed, 11 fasted 
cells from 6 fed and 5 fasted animals, p = 0.04 by unpaired t-test; Figure 3.5B inset). 
Additionally, when the initial current amplitudes were normalized to the last evoked current in 
the train, it became apparent that the peak (1st) current was relatively larger after fasting (fed = 
7.7 ± 0.98; fasting = 12.4 ± 1.71, p = 0.02 by unpaired t-test). Importantly, the refilling rates 
(steady state currents at the end of the train) are not significantly different between the groups 
(fed = 97.9 ± 28.4 pA, fasted = 81.5 ± 13.1, p = 0.63 by unpaired t-test). Thus, by multiple 
estimates, amplitudes, PPR and RRP size, it appears that fasting increased GABA release from 
AgRP neurons onto POMC neurons, although the possibility of postsynaptic contributions 
cannot be fully excluded.   
 
GAD activity is necessary for maintaining GABA release from NPY/AgRP neurons 
We next asked whether the activity of GAD could be directly responsible for the increase 
in GABA release from AgRP/NPY neurons. This was examined in primary hypothalamic neuron 
cultures made from NPY-hrGFP transgenic mice and recordings were made in cells possessing 
recurrent synapse (autapses). When the conformationally restricted glutamate analogue 
chelidonic acid (1 mM), a competitive, potent, and fast-acting GAD inhibitor (Porter & Martin, 
1985), was included in the pipette solution there was a significant inhibition of evoked autaptic 
GABA currents (17.5 ± 5.5% of baseline after 17 minutes, n = 5, p < 0.0001 by RMANOVA, 
minute 5-17 significantly lower than baseline using Dunnett’s multiple comparisons test; Figure 
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3.6A,C). Thus, GAD activity is a pivotal determinant of GABA release in NPY/AgRP neurons 
consistent with previous reports at other GABAergic synapses (Apostolides & Trussell, 2013).  
To verify that chelidonic acid was not reducing GABA release independent of its actions 
on GAD activity, GABA (10 mM) was included in the pipette along with the chelidonic acid in 
some recordings. The inclusion of GABA prevented the chelidonic acid-induced inhibition of the 
autaptic currents (117.8 ± 8.4% of baseline after 17 minutes, n = 5, p = 0.38 by RMANOVA, no 
minute significantly different than baseline using Dunnett’s multiple comparisons test; Figure 
3.6B-C), indicating that chelidonic acid inhibited GABA release by directly reducing GABA 
levels in the cytoplasm. The chelidonic acid-induced reduction in the evoked IPSC correlated 
with increased PPR over time consistent with decreased GABA release and this effect was absent 
when GABA was included in the pipette (n = 5, p = 0.02 by RMANOVA over time, minutes 14, 
15, and 17 significantly different between groups using Sidak’s multiple comparisons test; 
Figure 3.6D). 
 
Decreased Gad1 expression correlates with reduced probability of GABA release 
After observing the correlation between increased Gad1 expression and enhanced 
functional GABA release, we tested the hypothesis that decreased Gad expression would reflect 
decreased GABA release from this synapse. IP leptin injections were used to approximate a 
satiated state. Compared to saline-injected controls, leptin caused a significant decrease in the 
number of NPY-hrGFP immuno-labeled cells that were also labeled with the probe for Gad1 
mRNA (0.75 ± 0.03 for leptin normalized to control, n = 3, 4 mice, p = 0.035 by unpaired t-test; 
Figure 3.7A). Correspondingly, the proportion of NPY/AgRP neurons with strong Gad1 signal 
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was decreased in leptin-injected mice (Kolmogorov-Smirnov test, p=4.0012*10-18, n = 390 













 Optogenetic activation of NPY/AgRP neurons was again used to observe changes in 
probability of release. Leptin treatment caused a significant increase in PPR (0.90 ± 0.06 for 
saline, 1.30 ± 0.14 for leptin, n = 7 saline, 8 leptin from 3 saline-injected and 3 leptin-injected 
animals, p = 0.025 by unpaired t-test; Figure 3.7C) indicating a decrease in the probability of 
release. The peak amplitude of the first pulse in leptin-treated animals appeared to be less than in 
control tissue, but this was not statistically significant due to the high variance (324.63 ± 153.55 
Figure 3.6. Inhibiting the GAD enzyme reduces autaptic GABA release from NPY/AgRP cells in 
culture. Whole-cell recordings were made in NPY/AgRP cells that had formed autapses in culture. 
Addition of chelidonic acid (1 mM) in the pipette solution caused a significant inhibition of evoked 
GABA release over time (A). Adding GABA into the pipette along with the chelidonic acid prevented 
the decrease in eIPSC amplitude (B). Average amplitudes for each condition are plotted in (C) and 
average paired-pulse ratios are plotted in (D). Data are plotted as mean ± SEM. 
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pA for saline, 86.71 ± 21.55 pA for leptin, n = 7 saline, 8 leptin from 3 saline-injected and 3 
leptin-injected animals, p = 0.12 by unpaired t-test; Figure 3.7D). Together with the fasting 
results, the leptin-induced reduction in Gad1 and corresponding decrease in the probability of 
















Figure 3.7. Leptin injection decreases Gad1 in NPY/AgRP cells and decreases probability of GABA 
release. A single injection (IP) leptin 2 hours prior to tissue collection caused a significant decrease in the 
percent of NPY cells expressing detectable levels of Gad1 (A), as well as a decrease in the proportion of cells 
with high levels of Gad1 label intensity (B). Whole-cell recordings in POMC neurons in slice preparations show 
that leptin injection caused a significant increase in PPR when GABA release was light-evoked from NPY/AgRP 
terminals (C, averaged representative traces above respective bars). Peak amplitudes were not significantly 
different after leptin injection (D). Data are plotted as mean ± SEM. * = p <0.05. 
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3.5 Discussion 
The objective of the present study was to determine if a physiologic perturbation could 
cause a change in GABA release that is reflected in the overall expression of a GABAergic 
marker in situ. Focusing on the NPY/AgRP population of neurons with a known GABAergic 
phenotype whose activity is sensitive to energy balance, fasting was found to increase the 
expression of Gad1 mRNA in these neurons. Further, the enhanced mRNA expression correlated 
with an increase GABA transmission. It is likely that GABA release was increased at all 
terminals of NPY/AgRP neurons and that other conditions would also change Gad expression 
and GABA release from these neurons as indicated by the decrease in Gad expression and 
GABA release observed after leptin treatment. The expression of Gad1 mRNA may prove to be 
a useful proxy for GABA release in other systems.  
 
NPY/AgRP neurons and GABA release 
The present study focused on GABA release from AgRP/NPY neurons. These neurons 
were chosen because of the availability of tools to examine and control them, the ability to 
identify and record from a postsynaptic target neuron and because of the important role these 
neurons play in the regulation of energy balance (Parker & Bloom, 2012). Although the current 
work focused on NPY/AgRP/GABA to POMC neuron connections, it seems most likely that the 
fasting-induced increase and leptin-induced decrease in GABA release observed would be 
consistent for other terminals from these neurons throughout the brain. Previous studies have 
indicated that NPY/AgRP terminals in the paraventricular hypothalamus (Atasoy et al., 2012) or 
the parabrachial nucleus (Carter et al., 2013) account for the ability of NPY/AgRP neuron-
derived GABA to increase food intake, depending on the conditions studied. While NPY/AgRP 
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neuron-derived GABA can inhibit POMC neurons (Figure 3.3 and (Atasoy et al., 2012), this 
inhibition is reportedly not essential for the acute increase in feeding that results from 
experimental activation of NPY/AgRP neurons (Aponte et al., 2011; Atasoy et al., 2012). 
However, the possibility exists that under different conditions and/or timescales, changes in 
GABA input to POMC neurons may be an important factor in tilting energy balance in one 
direction or the other. What is clear at present is that GABA release from NPY/AgRP neurons is 
able to induce food intake and that both Gad1 mRNA and GABA release in these cells is 
dynamically regulated in an energy-state dependent manner.  
 
Correlating Gad67 mRNA and GABA tone 
Numerous studies indicate that Gad mRNA, particularly Gad1 mRNA, is sensitive to a 
variety of factors including steroids, stressors, glucose, insulin, seizure, lesions, cellular activity 
and GABA itself (Rimvall & Martin, 1992; 1994; McCarthy, 1995; Schwarzer & Sperk, 1995; 
Bowers et al., 1998; Mason et al., 2001; Pedersen et al., 2001; Patz et al., 2003). Separate studies 
have shown overall changes in regional GABA tone in response to many of these factors. 
However, we are aware of only one study showing a direct correlation between GABA release 
and Gad1 expression and that study used a Gad1 reporter system in cultured hippocampal slices 
as well as an olfactory bulb preparation (Lau & Murthy, 2012). Additional studies have shown 
that GAD activity or expression and corresponding changes in cytosolic GABA levels dictate the 
strength of GABAergic transmission in interneurons of the dorsal cochlear nucleus (Apostolides 
& Trussell, 2013) and in prefrontal cortex (Lazarus et al., 2013). Together with the present 
results in the hypothalamus using the physiological stimulus of fasting and leptin injection, it 
appears that changes in Gad mRNA and corresponding changes in protein levels for GAD may 
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closely reflect altered GABAergic transmission in many brain regions and cell types. Thus, at 
various synapses Gad may be a reasonable indicator of synaptic GABA levels.  
 It is important to note that, in addition to transcriptional regulation, the GAD enzymes are 
regulated by posttranslational modifications including coenzyme pyridoxal 5’ –phosphate (PLP) 
binding and phosphorylation (Wei & Wu, 2008). While we cannot rule out that these additional 
levels of regulation may be important determinants of cytosolic GABA and GABA release, 
transcription appears to be a key point of regulation, particularly for Gad1. In many systems, 
Gad1 mRNA levels are more sensitive to perturbations than Gad2 (McCarthy, 1995; Bowers et 
al., 1998; Mason et al., 2001; Patz et al., 2003). This differential dependence on transcriptional 
regulation likely reflects the observation that the majority of the 65 kD form of GAD 
(transcribed from Gad2) is maintained in the inactive apoenzyme form and thus is dependent on 
posttranslational activation by PLP, whereas GAD67 is maintained primarily in the active 
holoenzyme state (Wei & Wu, 2008) and is therefore more dependent on the level of expression 
rather than posttranslational modification. 
 In addition to GAD activity, cytosolic GABA levels may also be affected via GABA 
uptake through the plasma membrane-bound GABA transporters. While the autaptic studies 
presented here suggest that GAD activity is a key determinant of GABA release from 
NPY/AgRP cells, a possible contribution from altered GABA uptake cannot be ruled out. The 
promotion of self-synapses necessitates that the neurons be grown under relatively sparse 
conditions, which may preclude the presence of substantial extracellular GABA concentrations. 
It is difficult to know if GABA uptake plays an important role in the intact system, although 
previous studies in intact circuits found that chemical inhibition of GAD was sufficient to reduce 
GABA release (Apostolides & Trussell, 2013) and the majority of GABA for release comes from 
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glutamate decarboxylation (Mathews & Diamond, 2003, Martin & Tobin, 2000) suggesting a 
limited role for GABA uptake in synaptic release. Consistent with the importance of GABA 
content as a primary driver of vesicular uptake and release are the present results showing an 
increase in PPR and decrease in evoked GABA currents as GAD activity is interrupted by 
chelidonic acid.  
 
Broad potential for Gad mRNA as a proxy for GABAergic synaptic transmission 
There are many conditions in which it may be desirable to detect changes in Gad mRNA 
as a proxy for plasticity in GABAergic transmission. For example, the use of single or multi-
label in situ hybridization as used here allows for entire populations of cells to be examined in 
relatively intact tissue, which may be particularly useful in heterogeneous tissues or cell types. 
Further, semi-quantitative mRNA analysis of Gad could allow for an approximation of GABA 
tone when direct detection of GABA release is not technically feasible, such as when transgenic 
tools do not exist or when the postsynaptic target cannot be identified for paired recordings. 
While further studies will be needed to determine how generalizable the use of Gad mRNA will 
be as an indicator of GABA release from other cell types, the present studies together with past 
work indicate the potential for broad utility.  
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It is still a wonder to me how the essential act of eating, so basic in concept, is so 
mechanistically complex in mammals. Beyond the social and cultural factors that go into how 
people behave regarding food, understanding of the finely tuned biological processes required to 
signal healthy feeding and maintenance of a balanced energy set point is still an incomplete 
puzzle. The scientific community has come a long way since lesion experiments of the 1940s, 
when it was first determined that the hypothalamus played a large role in feeding behavior and 
energy balance, but there is still a lack of understanding when it comes to the true nature of the 
many relevant circuits present throughout the nervous system. Hopefully, this study has added a 
few good pieces to the puzzle to help understand the topic as a whole. After completion of the 
main project, the feeding and energy balance field now has a more robust understanding for the 
existence and regulation of amino acid transmitters released by first order feeding neurons, and 
we continue to investigate physiological roles in circuitry and subsequent phenotypes for which 
this release is most relevant. 
 
4.1 Summary, weaknesses, and future directions for presented research 
 Results from Chapter 2 provide evidence for both glutamate and GABA release in the 
ARC from POMC cells. Using a combined optogenetics-electrophysiology approach, transmitter 
release could be assayed in pseudo-paired recordings with native synaptic connections still 
intact. ChR2 was used in POMC cells to find connections to nearby downstream cells. Just like 
the spontaneous input onto POMC cells, POMC glutamate and GABA release can be affected 
through activation of presynaptic GPCRs. One weakness of the recording paradigm used is that it 
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takes an enormous amount of effort to collect a data set of acceptable size. So far, it is not known 
if POMC neurons heavily innervate any one cell type in a given region. The ARC was chosen as 
a downstream target region mainly because it was convenient to do so, in addition to not finding 
a higher connection rate when randomly patching in the PVN. Through the inevitable 
development of future single synapse anterograde tracers, it will be interesting to see exactly on 
which neurons POMC cells synapse, and will provide an avenue for quickly finding many 
postsynaptic targets to patch onto or study in other ways. Alternatively, clever use of an 
anterograde tracer that is targetable and travels a known number of synapses per amount of time 
could be used similarly (e.g. the vesicular stomatitis virus vectors discussed in Beier et al., 2011). 
These strategies will allow for experiments like completed with NPY/AgRP cells in Chapter 3 to 
be completed in a timely manner, even if POMC cells innervate a sparse subset of any one type 
of cell. It would be interesting to know if glutamate or GABA release changes in a fed or fasted 
state, because this would be another avenue for feeding signals to be relayed, especially when 
considering juxtaposition with the fast amino acid GABA release from NPY/AgRP neurons. 
Opposing POMC amino acid transmitters of excitation and inhibition could be differentially 
regulated to appropriately modulate downstream feeding areas. Perhaps the two subpopulations 
of cells are completely distinct, and only rarely does glutamatergic POMC output overlap with 
GABAergic targets. After all, simultaneous glutamatergic and GABAergic release onto a 
downstream cell was a very rare occurrence in the data collected for Chapter 2. 
Showing that POMC cells release both glutamate and GABA forces the scientific field to 
acknowledge both first order feeding neuron populations’ amino acid transmitters when 
designing experiments. Current and previous studies that have failed to take into account these 
findings must accept potential weaknesses in their proposed models and be open to alternate 
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interpretations of their results. With this new information, GABA originating in the ARC is not 
confined to a unilaterally orexigenic force (Figure 4.1). As a nascent topic of research, there is 
still a dearth of information on POMC cell amino acid transmitter release, which leaves the 
subject poised to be mined for valuable contributions to energy homeostasis. It is exciting to 
hypothesize that adjusting amino acid transmitter release in POMC cells could help to regain 
healthy physiology from a far too negative or positive energy balance. 
 Results from Chapter 3 continued to add to the growing body of knowledge pertaining to 
amino acid transmitter release from first order feeding neurons. It was discovered that 
GABAergic input specifically from NPY/AgRP cells onto POMC cells is affected by feeding 
state. It had been shown before that in a fasted state, GABA tone increases onto POMC cells 
after a fast (Vong et al., 2011), but since it is not known what fraction of the total GABA release 
onto POMC cells is accounted for by NPY/AgRP cells, it was uncertain if the increase in 
inhibition actually comes specifically from these orexigenic neurons. As has been hypothesized 
before, this would be one mechanism by which satiety signals from POMC cells could be 
blunted, while at the same time exciting hunger circuits. I.e., not only can GABA be used by 
NPY/AgRP cells in a hungry state to acutely turn down the activity of POMC cells, it can also 
affect other downstream targets like anorexigenic second order neurons in the PVN. 
While the discovery that there is a massive one-way connection of NPY/AgRP neurons to 
POMC neurons preceded the research in Chapter 3 (Atasoy et al., 2012), it was compelling to 
find this out first hand during my own research because it was still common to believe that there 
was direct reciprocal innervation between the neuronal populations (compare Figure 1.2 to 
Figure 4.1). In a healthy slice preparation with high viral penetrance and brightly labeled POMC 
cells, almost any eGFP-labeled cell would be downstream of GABA-releasing NPY/AgRP cell  
 67
  
Figure 4.1. Adjusted paradigm of first order feeding neurons. In the new paradigm of first order neurons, 
reciprocal innervation between POMC cells has been removed. GABA release from NPY/AgRP cells is adjusted 
based on feeding state and release onto downstream targets is important for appropriate function of the circuit. 
The POMC population releasing glutamate and/or GABA onto downstream cells has been added to the model. In 
addition, either type of first order neuron may synapse onto a downstream cell without symmetrical connection 
by the opposing population. Abbreviations: blood-brain barrier (BBB), NPY type 1 receptors (Y1R), 
melanocortin 4 receptor (MCR4). 
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inputs. This is in contrast to expressing ChR2 in POMC cells and never finding a single 
glutamatergic or GABAergic current evoked onto NPY/AgRP cells. It seems that the older 
reciprocal feedback hypothesis is dying out. This is significant because in the old model, POMC 
and NPY/AgRP neurons are supposed to be battling for dominance both with each other and at 
downstream inputs. This finding continues to push the idea that these are often two distinctly 
separate pathways that often act asymmetrically from one another. POMC cells could still feed 
back onto their orexigenic neighbors, but it would have to be through indirect input or maybe 
paracrine effects of peptide release. 
 One limitation of the experiments in Chapter 3 is that all recordings were made at 
POMCNPY/AgRP synapses. One set of future experiments would be to test other synaptic 
contacts located in other nuclei in order to determine if the increase in excitation observed after a 
fast translates to increased GABA release at all downstream inputs. Through these experiments, 
it could be determined if GABA release is regulated similarly at synaptic connections in both 
melanocortin -dependent and -independent pathways. It would also be important to extrapolate 
the synaptic physiology observed beyond the single synapse studied in order to continue 
validation of the Gad mRNA proxy hypothesis. The finding that the increase or decrease in Gad1 
message after a fast or leptin injection was a good correlate for increased functional GABA 
release might be a valuable tool for many projects. As a newer hypothesis, although as discussed 
in Chapter 3, not without rationale or additional support, this idea needs to be measured at the 
synaptic level and replicated across many areas in the brain. We also still do not know for certain 
if more Gad1 mRNA actually means more GAD67, and that any additional GAD67 is 
responsible for the observed increase in GABA release. While we observed an increase in 
mRNA, and subsequently showed that depletion of functional GAD from a cell reduces GABA 
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release, it is still a correlative finding. While establishing both broad applicability and a solid 
mechanistic link are important, we focused more on showing that the mRNA-as-proxy could be 
used for both increases and decreases in GABA release (by using fasted state and leptin 
injections), and that Gad1 tracks better with GABA release than Gad2 (responsible for the 
GAD65 protein). As a future topic beyond the scope of the primary findings, knowing exactly 
what cells each group of opposing feeding neuron types synapse onto in downstream regions will 
provide valuable drug target information, as well as elucidate how both cell populations 
appropriately coordinate their amino acid transmitter release. For example, with the finding that 
both first order cell types use GABA as their primary amino acid transmitter, it would be odd if 
differential regulation of GABA occurred depending on feeding state in both POMC and AgRP 
cells, only to have projections from both cell types going to the same downstream cell. No matter 
what energy state the animal is in, the GABA would be released onto this hypothetical 
downstream cell. Future studies, perhaps using new tracer technology, could be used to fully 
explore this aspect of the circuitry. 
 
4.2 Related experiments 
GABA released onto POMC neurons 
 One of the questions left unanswered in Chapter 3 is how much of the total GABA input 
onto POMC neurons comes from NPY/AgRP neurons. It should be noted that some hypothesize 
that this source of POMC cell inhibition is relatively unimportant because selective activation of 
both NPY/AgRP and POMC neurons at the same time induces feeding to the same extent as 
activating NPY/AgRP cells alone (implying that inhibition of POMC neurons is not a significant 
contributor to increased food intake; Atasoy et al., 2012). While this was not necessarily a bad 
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experiment, the results do not warrant dismissing any relevance for acute inhibition of POMC 
neurons in food intake.  It is not too surprising that acute maximal activation of both populations 
of first order feeding neurons, causes the biological imperative of energy consumption to win 
out; the effects of extraphysiological activation of NPY/AgRP neurons and subsequent 
transmitter release could trump POMC amino acid release, and POMC peptide release after 
chronic activation is not adequately considered. The interpretation of the specific experiment 
says more about the importance physiology puts on maintaining adequate energy stores than it 
does about the inhibition of POMC neurons by NPY/AgRP neurons. It is hard to believe that the 
significant effect that activation of NPY/AgRP cells expressing ChR2 has on POMC cell 
physiology (Figure 3.3) would not have physiological consequences if activation were not at a 
ceiling. A more nuanced set of experiments, where parameters are being manipulated within 
physiological dynamic ranges, is likely needed to test the true relevance of NPY/AgRP GABA 
tone on POMC cells. In any case, for the tuning of GABA release to have a relevant impact on 
POMC cell physiology, it is important to know that a large fraction of inhibitory tone onto 
POMC neurons is due to the release of GABA from NPY/AgRP cells. One early idea for 
answering this question involved expressing the hyperpolarizing light-sensitive Cl--specific ion 
pump, halorhodopsin, in AgRP-Cre animals. Instead of exciting the cells with blue light so they 
would release GABA onto POMC cells, we could look at spontaneous GABA input onto POMC 
cells both before and after inhibition specifically of the NPY/AgRP cell population. We were 
apprehensive of this idea, though, as most of the GABA release onto POMC cells is action 
potential-independent i.e. most sIPSCs would remain as mIPSCs after application of TTX (Pinto 
et al., 2004; Pennock and Hentges, 2011), meaning hyperpolarization of NPY/AgRP somas with 
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halorhodopsin might just return inconclusive results. In lieu of this approach, we decided to use a 
vesicular GABA transporter (VGAT) knockout targeted to NPY/AgRP neurons. 
Using a cross between an AgRP-Cre animal and a Vgatflox/flox animal, POMC cells could 
be recorded from in the same configuration as seen throughout Chapter 3 (requiring ChR2 
expression and another cross so POMC cells could be visually targeted) and observed for 
spontaneous GABA input. After it was determined that GABA could not be light-evoked from 
NPY/AgRP cells (0/14 cells patched showed a light-evoked current), spontaneous IPSCs were 
compared between AgRP-Cre; Vgatflox/flox; POMC-eGFP and AgRP-Cre; POMC-eGFP animals 
(Figure 4.2A-B). Interestingly, there was no difference between groups in either frequency or 
amplitude of spontaneous IPSCs (7.6 ± 1.5 Hz in control, 6.5 ± 2.0 Hz in experimental, n = 9 
cells from 3 control and 3 experimental animals, p = 0.66 by unpaired t-test; Figure 4.2C. 50.7 ± 
6.5 pA in control, 54.0 ± 7.7 pA in experimental, n = 9 cells from 3 control and 3 experimental 
animals, p = 0.74 by unpaired t-test; Figure 4.2D), suggesting that release from NPY/AgRP cells 
make up almost none inhibitory GABA tone seen by POMC cells. However, because this was 
not an inducible strategy and thus GABA release from a normal source was not available during 
development, there may have been some input compensation from other sources that prevented 
an accurate assessment of NPY/AgRP GABA release. This is a reasonable possibility given data 
to support to the existence of compensatory, redundant mechanisms in place to protect an animal 
from failing to consume a necessary caloric load. It is already accepted that global genetic 
deletions of NPY and/or AgRP, as well as directed knockout of Vgat from NPY/AgRP neurons 



















To get around developmental compensation, another transgenic approach was used. 
Instead of Vgatflox/flox, a floxed µ-opioid receptor (MOR) animal was used. Previous work 
indicates that a saturating concentration of MOR agonist at this synapse in a brain slice 
preparation causes a ~75% reduction in spontaneous IPSCs (Pennock and Hentges, 2011). With 
MORs deleted specifically in NPY/AgRP cells, inhibition of presynaptic release can be 
compared between experimental and control animals, with less inhibition in the experimental 
condition meaning a larger contribution of GABA inputs from NPY/AgRP neurons. At the time 
Figure 4.2. Spontaneous GABA release onto POMC cells is unaffected by 
removing the ability of NPY/AgRP cells to release GABA. Representative traces of 
spontaneous GABA-mediated IPSCs in POMC neurons in tissue from AgRP-Cre; 
POMC-eGFP (A) and AgRP-Cre; POMC-eGFP; Vgatflox/flox (B) mice. sIPSC 
frequency was not significantly different between groups (C), nor were current 
amplitudes (D). Data are plotted as mean ± SEM. 
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of this writing, these experiments are ongoing, but preliminary results indicate that there is a 
significant portion of GABA input onto POMC neurons by NPY/AgRP neurons. 
 
Relevance of POMC cell amino acid neurotransmitters 
 While mice with POMC cells that are GABA release-deficient have not been developed 
yet, I was able to play a role in a study that looked at the physiological relevance of glutamate 
release (Dennison et al., 2015). This study was divided mainly into two parts. First, it was 
discovered that mRNA for the vesicular glutamate transporter vGlut2 is highly colocalized with 
POMC expression early in development, and then tapers off as mice age into adulthood. The 
second part of the study involved deletion of vGlut2 specifically from POMC neurons. When fed 
a high-fat diet, male mice without vGlut2 expressed in their POMC neurons were not able to 
maintain their body weight, while female mice were unaffected (Figure 4.3). While this result 
suggests a physiologic role for glutamate release from POMC neurons in the maintenance of 
body weight on a high-fat diet, at least in males, care must be taken to consider the caveats of an 
interpretation limited to adult glutamate release. As discussed in Chapter 1, these genetic crosses 
that cause Cre expression whenever the POMC gene is turned on may make for convoluted 
results. The phenotype observed could be caused by glutamate acting as an important trophic 
factor early in development. Alternatively, neurons fated to be kisspeptin neurons, a 
subpopulation of ARC cells which express POMC early on, could have had their vGlut2 knocked 
out by Cre resulting from the transient expression of the POMC promoter in neurons that are not 
authentic POMC neurons (Padilla et al., 2012). While this study hasn’t provided a fully 
satisfying answer for the importance of POMC neuron glutamate release in adult animals, it is an 
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interesting first step. Experiments are ongoing using an inducible POMC-Cre line of mice to 


















Amino acid transmitter release from POMC cells in the NTS 
 As mentioned in Chapter 1, in addition to the POMC cells located in the ARC, there is an 
additional neuronal population of POMC cells located in the medulla’s NTS (Bronstein et al., 
1992; Padilla et al., 2012). It is unknown, however, if this group of cells expresses POMC at any 
meaningful level in adulthood, since POMC mRNA cannot be detected past early postnatal 
Figure 4.3. vGlut2 deletion in POMC neurons increases weight gain in males on a high-fat 
diet. A–D: Weight curves of control mice (blackcircles) and mice lacking vGlut2 in POMC 
neurons maintained on normal chow (A,C) or high-fat diet (B,D). All data points are mean ± SEM. 
* = p < 0.05 compared to same age control mice (vGlut2flox/flox). Reproduced with permission from 
Dennison et al., 2015) 
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development. Nonetheless POMC-eGFP and POMC-Cre transgenes are expressed in the NTS, 
making this group of neurons targetable and able to be manipulated. This population of POMC 
cells’ role in food intake and energy balance still is not completely clear, but recent research 
suggests that they play a role in cessation of feeding on a short-term timescale (Zhan et al., 
2013). In light of this information and the knowledge that POMC neurons in the ARC release 
GABA and glutamate, we tested the hypothesis that amino acid transmitter release from POMC 
cells within the NTS, rather than peptide release, may mediate the physiologic response observed 
by Zhang et al. We used an approach similar to the blind patching in Chapter 2. An AAV 
containing the double-floxed inverted ChR2 construct was injected into the NTS of POMC-Cre 
animals, and after an incubation period, live sagittal slices were cut and were recorded from. 
Although exceedingly rare, both glutamate and GABA release were observed in this preparation 
(Figure 4.4). This might be one way in which these feeding neurons exert short-term feeding 
effects, but there exists one major caveat to these findings. Both in the case of Zhan et al., 2013 
and our experiment, a POMC-Cre animal is used to express the proteins crucial to testing 
hypotheses about NTS POMC cells, whereas an in situ hybridization approach was used to verify 
that POMC neurons expressed markers for GABAergic and glutamergic phenotypes. The in situ 
hybridization approach relied on the detection of eGFP driven by the POMC promoter since it is 
not possible to readily detect endogenous POMC mRNA or protein. In attempting to verify that 
POMC-Cre and POMC-eGFP are expressed in the same cells, it became apparent that 
completely distinct populations of cells actually express POMC-Cre and POMC-eGFP —there is 
no overlap at all (unpublished findings). Although concerning, this is not completely surprising 
since the Padilla et al., 2012 study found similar results. In this corroborating instance, it was 
found that the population of cells labeled by performing immunohistochemistry for eGFP in a 
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POMC-eGFP animal was completely distinct from the population of cells labeled by the 
expression of a Cre-dependent fluorophore in POMC-neurons. Taken together, it appears that 
there are distinct populations of cells marked by the expression of POMC-Cre and POMC-eGFP. 
Based on functional studies, POMC-Cre neurons likely play a role in proper food intake, but the 



















Figure 4.4. GABA and glutamate are released by NTS POMC-Cre neurons. Cells 
nearby ChR2-expressing NTS POMC-Cre cell bodies were patched while light evoking 
transmitter release. Both GABA and glutamate currents were observed (A-B, left). BMI 
and DNQX were able to ablate each current, respectively (A-B, right). Black marks 
indicate a short flash of blue light. 
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4.3 Final remarks 
 Altogether, this study adds substantial evidence to support the growing idea that amino 
acid transmitters are essential to proper function of the so-called first order feeding neurons. We 
have provided compelling evidence that glutamate and GABA are released from POMC cells 
within their native circuits, and are just beginning to understand the physiological relevance of 
this release. We also discovered that GABA release from NPY/AgRP cells is modulated based of 
feeding state, and that in situ hybridization for Gad mRNA matches these findings suggesting 
that mRNA may be a useful proxy for functional GABA release in this, and perhaps other brain 
regions. I speculate that the feeding and energy balance field will continue to discover the 
importance of amino acid transmitter release from first order feeding neurons. Sensing energy 
state through circulating factors and afferent inputs, and subsequently signaling for the proper 
behavioral and autonomic adjustments requires a finely tuned and complex system. The fast 
neurotransmission provided by amino acid transmitters is an important part of this system, and is 
exquisitely poised to work in concert with the relatively slower peptide release to maintain 
healthy physiology. With better understanding of every component that makes up the neural 
circuitry of energy homeostasis, we will be able to provide better tools to fight for the correction 
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AA   Amino acid 
AAV   Adeno-associated virus 
aBNST  Anterior bed nucleus of the stria terminalis 
aCSF   Artificial cerebrospinal fluid 
ACTH   Adrenocorticotropic hormone 
AgRP   Agouti-related protein 
ARC   Arcuate nucleus of the hypothalamus 
BMI Body mass index in introduction, Bicuculline methiodide, a GABAA 
receptor antagonist, elsewhere 
CCK   Cholecystokinin, an anorexigenic gut peptide 
CGP (2S)-3-[[(1S)-1-(3,4-Dichlorophenyl)ethyl]amino-2-
hydroxypropyl](phenylmethyl)phosphinic acid, a GABAB receptor 
antagonist 
ChR2   Channelrhodopsin-2, a light-gated cation channel 
CNO   Clozapine-N-oxide, main DREADD agonist 
CTAP D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2, a µ-opioid receptor-
specific antagonist 
CVO   Circumventricular organ 
db/db   Leptin receptor-deficient mouse strain 
DAMGO [D-Ala2, N-Me-Phe4, Gly5-ol]-enkephalin, µ-opioid receptor-specific 
agonist 
DMH   Dorsomedial nucleus of the hypothalamus 
DNQX 6,7-dinitroquinoxaline-2,3(1H,4H), an AMPA and kainite channel 
antagonist 
DOR δ-opioid receptor 
DPDPE [D-Pen2,5]enkephalin, a δ-opioid receptor-specific agonist 
DREADD  Designer receptor exclusively activated by designer drug 
GABA   γ-aminobutyric acid 
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GAD   Glutamate decarboxylase, an enzyme that converts glutamate to GABA 
GAT   Plasma membrane GABA transporter 
Gad1 and 2  Messenger RNA for GAD67 and 65, respectively 
GLP-1   Glucagon-like peptide-1, an anorexigenic gut peptide 
GPCR   G-protein coupled receptor 
GRP   Gastrin-releasing peptide 
hrGFP   Humanized Renilla reniformis green fluorescent protein 
IP   Intraperitoneal 
IP3   Inositol trisphosphate 
IR   Immunoreactivity 
KOR   κ-opioid receptor 
LepRb   Leptin receptor, active long-form version 
LH   Lateral nucleus of the hypothalamus 
ME   Median eminence 
MOR   µ-opioid receptor 
MSH   Melanocyte stimulating hormone 
MTII   Melanotan-II, a melanocortin receptor agonist 
Nor-BNI  Nor-binaltorphimine, a κ-opioid receptor-specific antagonist 
NPY   Neuropeptide Y 
NTS   Nucleus tractus solitarius or Nucleus of the solitary tract 
ob/ob   Leptin-deficient mouse strain 
PBS   Phosphate-buffered saline 
PBN   Parabrachial nucleus 
PLC   Phospholipase C 
PLP   Pyridoxal 5’ –phosphate 
POMC   Proopiomelanocortin 
PPR   Paired-pulse ratio 
PSC   Postsynaptic Current—may be inhibitory (IPSC) or excitatory (EPSC) 
PVN   Paraventricular nucleus of the hypothalamus 
PYY   Peptide YY or Peptide tyrosine tyrosine, an anorexigenic gut peptide 
RRP   Readily releasable pool 
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TTX   Tetrodotoxin 
U69593 (+)-(5α,7α,8β)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-
benzeneacetamide, a κ-opioid receptor-specific agonist 
vGAT Vesicular GABA transporter 
VMH   Ventromedial nucleus of the hypothalamus 
 
 
